Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.Bone and Bones: A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principle cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX.Bone Remodeling: The continuous turnover of BONE MATRIX and mineral that involves first an increase in BONE RESORPTION (osteoclastic activity) and later, reactive BONE FORMATION (osteoblastic activity). The process of bone remodeling takes place in the adult skeleton at discrete foci. The process ensures the mechanical integrity of the skeleton throughout life and plays an important role in calcium HOMEOSTASIS. An imbalance in the regulation of bone remodeling's two contrasting events, bone resorption and bone formation, results in many of the metabolic bone diseases, such as OSTEOPOROSIS.Bone Density: The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS.Bone Resorption: Bone loss due to osteoclastic activity.Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.Bone Marrow Cells: Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.Bone Development: The growth and development of bones from fetus to adult. It includes two principal mechanisms of bone growth: growth in length of long bones at the epiphyseal cartilages and growth in thickness by depositing new bone (OSTEOGENESIS) with the actions of OSTEOBLASTS and OSTEOCLASTS.Bone Diseases: Diseases of BONES.Bone Regeneration: Renewal or repair of lost bone tissue. It excludes BONY CALLUS formed after BONE FRACTURES but not yet replaced by hard bone.Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Bone Matrix: Extracellular substance of bone tissue consisting of COLLAGEN fibers, ground substance, and inorganic crystalline minerals and salts.Polyvinyl Alcohol: A polymer prepared from polyvinyl acetates by replacement of the acetate groups with hydroxyl groups. It is used as a pharmaceutic aid and ophthalmic lubricant as well as in the manufacture of surface coatings artificial sponges, cosmetics, and other products.Gelatin: A product formed from skin, white connective tissue, or bone COLLAGEN. It is used as a protein food adjuvant, plasma substitute, hemostatic, suspending agent in pharmaceutical preparations, and in the manufacturing of capsules and suppositories.Embolization, Therapeutic: A method of hemostasis utilizing various agents such as Gelfoam, silastic, metal, glass, or plastic pellets, autologous clot, fat, and muscle as emboli. It has been used in the treatment of spinal cord and INTRACRANIAL ARTERIOVENOUS MALFORMATIONS, renal arteriovenous fistulas, gastrointestinal bleeding, epistaxis, hypersplenism, certain highly vascular tumors, traumatic rupture of blood vessels, and control of operative hemorrhage.Microspheres: Small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various reagents acting as tags or markers.Iridoid Glycosides: A subclass of iridoid compounds that include a glycoside moiety, usually found at the C-1 position.PolyvinylsHematoxylin: A dye obtained from the heartwood of logwood (Haematoxylon campechianum Linn., Leguminosae) used as a stain in microscopy and in the manufacture of ink.Growth Plate: The area between the EPIPHYSIS and the DIAPHYSIS within which bone growth occurs.Ribs: A set of twelve curved bones which connect to the vertebral column posteriorly, and terminate anteriorly as costal cartilage. Together, they form a protective cage around the internal thoracic organs.Inhalation: The act of BREATHING in.Bronchoconstrictor Agents: Agents causing the narrowing of the lumen of a bronchus or bronchiole.Neoplasms, Bone Tissue: Neoplasms composed of bony tissue, whether normal or of a soft tissue which has become ossified. The concept does not refer to neoplasms located in bones.Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.Neoplasms, Connective and Soft Tissue: Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.Neoplasms, Gonadal Tissue: Neoplasms composed of tissues of the OVARY or the TESTIS, not neoplasms located in the ovaries or testes. Gonadal tissues include GERM CELLS, cells from the sex cord, and gonadal stromal cells.Neoplasms, Adipose Tissue: Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.Neoplasms, Nerve Tissue: Neoplasms composed of nerve tissue. This concept does not refer to neoplasms located in the nervous system or its component nerves.Device Removal: Removal of an implanted therapeutic or prosthetic device.Gram-Positive Bacterial Infections: Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.Suppuration: A pathologic process consisting in the formation of pus.Knee Joint: A synovial hinge connection formed between the bones of the FEMUR; TIBIA; and PATELLA.Search Engine: Software used to locate data or information stored in machine-readable form locally or at a distance such as an INTERNET site.Gram-Positive Bacteria: Bacteria which retain the crystal violet stain when treated by Gram's method.Translational Medical Research: The application of discoveries generated by laboratory research and preclinical studies to the development of clinical trials and studies in humans. A second area of translational research concerns enhancing the adoption of best practices.Awards and PrizesNational Institutes of Health (U.S.): An operating division of the US Department of Health and Human Services. It is concerned with the overall planning, promoting, and administering of programs pertaining to health and medical research. Until 1995, it was an agency of the United States PUBLIC HEALTH SERVICE.Political Systems: The units based on political theory and chosen by countries under which their governmental power is organized and administered to their citizens.Democracy: A system of government in which there is free and equal participation by the people in the political decision-making process.National Center for Health Statistics (U.S.): A center in the PUBLIC HEALTH SERVICE which is primarily concerned with the collection, analysis, and dissemination of health statistics on vital events and health activities to reflect the health status of people, health needs, and health resources.International Classification of Diseases: A system of categories to which morbid entries are assigned according to established criteria. Included is the entire range of conditions in a manageable number of categories, grouped to facilitate mortality reporting. It is produced by the World Health Organization (From ICD-10, p1). The Clinical Modifications, produced by the UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES, are larger extensions used for morbidity and general epidemiological purposes, primarily in the U.S.Jaw: Bony structure of the mouth that holds the teeth. It consists of the MANDIBLE and the MAXILLA.Databases, Factual: Extensive collections, reputedly complete, of facts and data garnered from material of a specialized subject area and made available for analysis and application. The collection can be automated by various contemporary methods for retrieval. The concept should be differentiated from DATABASES, BIBLIOGRAPHIC which is restricted to collections of bibliographic references.Clinical Coding: Process of substituting a symbol or code for a term such as a diagnosis or procedure. (from Slee's Health Care Terms, 3d ed.)Jaw DiseasesMandibular Neoplasms: Tumors or cancer of the MANDIBLE.Lipoma: A benign tumor composed of fat cells (ADIPOCYTES). It can be surrounded by a thin layer of connective tissue (encapsulated), or diffuse without the capsule.Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.Bone Marrow Examination: Removal of bone marrow and evaluation of its histologic picture.Janus Kinase 2: A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.Bone Marrow Neoplasms: Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.

Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. (1/5419)

32p and 89Sr have been shown to produce significant pain relief in patients with skeletal metastases from advanced cancer. Clinically significant pancytopenia has not been reported in doses up to 12 mCi (444 MBq) of either radionuclide. To date, no reports comparing the relative efficacy and toxicity of the two radionuclides in comparable patient populations have been available. Although a cure has not been reported, both treatments have achieved substantial pain relief. However, several studies have used semiquantitative measures such as "slight," "fair," "partial" and "dramatic" responses, which lend themselves to subjective bias. This report examines the responses to treatment with 32P or 89Sr by attempting a quantification of pain relief and quality of life using the patients as their own controls and compares toxicity in terms of hematological parameters. METHODS: Thirty-one patients with skeletal metastases were treated for pain relief with either 32P (16 patients) or 89Sr (15 patients). Inclusion criteria were pain from bone scan-positive sites above a subjective score of 5 of 10 despite analgesic therapy with narcotic or non-narcotic medication, limitation of movement related to the performance of routine daily activity and a predicted life expectancy of at least 4 mo. The patients had not had chemotherapy or radiotherapy during the previous 6 wk and had normal serum creatinine, white cell and platelet counts. 32P was given orally as a 12 mCi dose, and 89Sr was given intravenously as a 4 mCi (148 MBq) dose. The patients were monitored for 4 mo. RESULTS: Complete absence of pain was seen in 7 of 16 patients who were given 32P and in 7 of 15 patients who were given 89Sr. Pain scores fell by at least 50% of the pretreatment score in 14 of 16 patients who were given 32P and 14 of 15 patients who were given 89Sr. Mean duration of pain relief was 9.6 wk with 32P and 10 wk with 89Sr. Analgesic scores fell along with the drop in pain scores. A fall in total white cell, absolute granulocyte and platelet counts occurred in all patients. Subnormal values of white cells and platelets were seen in 5 and 7 patients, respectively, with 32P, and in 0 and 4 patients, respectively, after 89Sr therapy. The decrease in platelet count (but not absolute granulocyte count) was statistically significant when 32P patients were compared with 89Sr patients. However, in no instance did the fall in blood counts require treatment. Absolute granulocyte counts did not fall below 1000 in any patient. There was no significant difference between the two treatments in terms of either efficacy or toxicity. CONCLUSION: No justification has been found in this study for the recommendation of 89Sr over the considerably less expensive oral 32P for the palliation of skeletal pain from metastases of advanced cancer.  (+info)

A fluorescent orthotopic bone metastasis model of human prostate cancer. (2/5419)

Here, we report a fluorescent spontaneous bone metastatic model of human prostate cancer developed by surgical orthotopic implantation of green fluorescent protein (GFP)-expressing prostate cancer tissue. Human prostate cancer PC-3 cells were transduced with the pLEIN expression retroviral vector containing the enhanced GFP and neomycin resistance genes. Stable GFP high-expression PC-3 clones were selected in vitro with G418, which were then combined and injected s.c. in nude mice. For metastasis studies, fragments of a single highly fluorescent s.c. growing tumor were implanted by surgical orthotopic implantation in the prostate of a series of nude mice. Subsequent micrometastases and metastases were visualized by GFP fluorescence throughout the skeleton, including the skull, rib, pelvis, femur, and tibia The central nervous system, including the brain and spinal cord, was also involved with tumor, as visualized by GFP fluorescence. Systemic organs, including the lung, plural membrane, liver, kidney, and adrenal gland, also had fluorescent metastases. The metastasis pattern in this model reflects the bone and other metastatic sites of human prostate cancer. Thus, this model should be very useful for the study and development of treatment for metastatic androgen-independent prostate cancer.  (+info)

Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. (3/5419)

We determined the effects of the potent bisphosphonate ibandronate in a murine model of human myeloma bone disease. In this model, bone lesions typical of the human disease develop in mice following inoculation of myeloma cells via the tail vein. Treatment with ibandronate (4 micrograms per mouse per day) significantly reduced the occurrence of osteolytic bone lesions in myeloma-bearing mice. However, ibandronate did not prevent the mice from developing hindlimb paralysis and did not produce a detectable effect on survival. There was no significant effect of ibandronate on total myeloma cell burden, as assessed by morphometric measurements of myeloma cells in the bone marrow, liver, and spleen, or by measurement of serum IgG2b levels. These results support clinical findings that bisphosphonates may be useful for the treatment of myeloma-associated bone destruction, but suggest that other therapies are also required to reduce tumor growth.  (+info)

Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. (4/5419)

Bombesin-like peptides such as gastrin-releasing peptide (GRP) have been shown to play a role in cancer as autocrine growth factors that stimulate tumor growth through specific receptors. To search for potential clinical indications for GRP analogues, it is important to identify human tumor types expressing sufficient amounts of the respective receptors. In the present study, we have evaluated the expression of GRP receptors in human nonneoplastic and neoplastic prostate tissues using in vitro receptor autoradiography on tissue sections with 125I-Tyr4-bombesin as radio-ligand. GRP receptors were detected, often in high density, in 30 of 30 invasive prostatic carcinomas and also in 26 of 26 cases of prostatic intraepithelial proliferative lesions, corresponding mostly to prostatic intraepithelial neoplasias. Well-differentiated carcinomas had a higher receptor density than poorly differentiated ones. Bone metastases of androgen-independent prostate cancers were GRP receptor-positive in 4 of 7 cases. Conversely, GRP receptors were identified in only a few hyperplastic prostates and were localized in very low density in glandular tissue and, focally, in some stromal tissue. In all of the cases, the receptors corresponded to the GRP receptor subtype of bombesin receptors, having high affinity for GRP and bombesin and lower affinity for neuromedin B. These data demonstrate a massive GRP receptor overexpression in prostate tissues that are neoplastically transformed or, like prostatic intraepithelial neoplasias, are in the process of malignant transformation. GRP receptors may be markers for early molecular events in prostate carcinogenesis and useful in differentiating prostate hyperplasia from prostate neoplasia Such data may not only be of biological significance but may also provide a molecular basis for potential clinical applications such as GRP-receptor scintigraphy for early tumor diagnosis, radiotherapy with radiolabeled bombesin-like peptide analogues, and chemotherapy with cytotoxic bombesin analogues.  (+info)

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. (5/5419)

PURPOSE: To evaluate the prognostic significance of a bone scan index (BSI) based on the weighted proportion of tumor involvement in individual bones, in relation to other factors and to survival in patients with androgen-independent prostate cancer. PATIENTS AND METHODS: Baseline radionuclide bone scans were reviewed in 191 assessable patients with androgen-independent disease who were enrolled onto an open, randomized trial of liarozole versus prednisone. The extent of skeletal involvement was assessed by scoring each scan using the BSI and independently according to the number of metastatic lesions. The relationship of the scored bone involvement to other known prognostic factors was explored in single- and multiple-variable analyses. RESULTS: In single-variable analyses, the pretreatment factors found to be associated with survival were age (P = .0446), performance status (P = .0005), baseline prostate-specific antigen (P = .0001), hemoglobin (P = .0001), alkaline phosphatase (P = .0002), AST (P = .0021), lactate dehydrogenase (P = .0001), and treatment (P = .0098). The extent of osseous disease was significant using both the BSI (P = .0001) and the number of lesions present (P = .0001). In multiple-variable proportional hazards analyses, only BSI, age, hemoglobin, lactate dehydrogenase, and treatment arm were associated with survival. When the patient population was divided into three equal groups, with BSI values of < 1.4%, 1.4% to 5.1%, and > 5.1%, median survivals of 18.3, 15.5, and 8.1 months, respectively, were observed (P = .0079). CONCLUSION: The BSI quantifies the extent of skeletal involvement by tumor. It allows the identification of patients with distinct prognoses for stratification in clinical trials. Further study is needed to assess the utility of serial BSI determinations in monitoring treatment effects. The BSI may be particularly useful in the evaluation of agents for which prostate-specific antigen changes do not reflect clinical outcomes accurately.  (+info)

Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report. (6/5419)

BACKGROUND: Some biochemical markers of bone turnover are expected to reflect the disease activity of metastatic bone tumor. In the present study six biochemical markers were evaluated to determine appropriate markers for the detection of metastatic bone tumors from breast cancer (BC). METHODS: A panel of bone turnover markers was assessed in 11 normocalcemic patients with bone metastases from BC and in 19 BC patients without clinical evidence of bone metastases. Bone formation was investigated by measuring serum bone isoenzyme of alkaline phosphatase (BALP), osteocalcin (OC) and carboxy-terminal propeptide of type I procollagen (PICP): Bone resorption was investigated by measuring serum carboxy-terminal telopeptide of type I collagen (ICTP), fasting urinary pyridinoline (Pyr) and deoxypyridinoline (D-Pyr). RESULTS: PICP was influenced by age and menopausal status. Significant correlations were observed between each of bone turnover markers except between BALP and OC. The mean levels of the six bone turnover markers were higher in patients with bone metastases than in those without them and significance was observed except for OC. The best diagnostic efficiency by receiver-operating characteristic (ROC) analysis was provided by ICTP followed by Pyr or D-Pyr, BALP, PICP and OC and significance was observed between ICTP and OC. Multiple logistic regression analysis adjusted by age revealed that the only significant marker related to bone metastases was ICTP. CONCLUSIONS: Serum ICTP appears to be the leading marker of bone metastases from BC. However, to reveal the clinical usefulness of these markers, further examination will be needed to account for the ease and cost-effectiveness of the measurements.  (+info)

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. (7/5419)

BACKGROUND: To apply our preclinical findings of cytotoxic synergy with the combination of estramustine phosphate (EP) and docetaxel as the basis of treatment of hormone refractory metastatic prostate cancer in man. To determine the optimal dosage and the toxicities of these two agents for future trials. PATIENTS AND METHODS: Seventeen patients with hormone refractory metastatic prostate cancer who were ambulatory with performance status < or = 2, normal marrow, renal and hepatic function were entered. Prior exposure to EP or a taxane were exclusion factors. EP was given orally at a dose of 14 mg/kg of body weight daily with concurrent docetaxel administered every 21 days as an intravenous infusion over 1 hour with dexamethasone 8 mg. PO BID for five days. EP dosages were kept static; docetaxel dosages were explored in a minimum of three patients per level for dosages of 40, 60, 70, and 80 mg/m2. Patients were evaluated weekly. Prostate specific antigen (PSA) was measured every three weeks. RESULTS: Five patients were entered at a docetaxel dose of 40 mg/m2, three at 60 mg/m2, six at 70 mg/m2, and three at 80 mg/m2. Only one patient had received prior chemotherapy. Grades 1 or 2 hypocalcemia and hypophosphatemia were seen at all dosage levels. Other grade 2 or less toxicities not related to dosage included alopecia, anorexia, stomatitis, diarrhea, and epigastric pain. Dose limiting toxicities (DLT) as grade 4 leukopenia and grade 4 fatigue were seen at 80 mg/m2. The phase II dose was defined at 70 mg/m2 with rapidly reversible leukopenia and minor liver function abnormalities. At this dosing level, dose intensity was 88% and 86% over consecutive cycles for docetaxel and EP, respectively. Two vascular events occurred at this dose level (70 mg/m2): one arterial and the other venous. PSA decreases greater than 50% from baseline were seen in 14 of 17 patients at all dosage levels. Four of the 17 patients demonstrated a complete biochemical response (PSA < or = 4 ng/ml). One patient had a partial response with measurable lung and liver lesions. CONCLUSION: EP given continuously with every three-week docetaxel at a dose of 70 mg/m2 is tolerable with evidence of antitumor activity based upon significant declines in PSA in the majority of patients and improvement of lung metastasis in one patient. Larger phase II studies of this combination in a homogenous population are warranted.  (+info)

Treatment of localized primary non-Hodgkin's lymphoma of bone in children: a Pediatric Oncology Group study. (8/5419)

PURPOSE: The treatment of primary lymphoma of bone (PLB) in children has traditionally included radiotherapy to the primary site; more recently, it has included systemic chemotherapy. Because of concern about the untoward effects of treatment in a disease that is curable, we attempted to determine whether radiotherapy can be safely excluded from treatment. PATIENTS AND METHODS: The results of three consecutive Pediatric Oncology Group (POG) studies were examined to determine the impact on outcome of radiotherapy as adjunctive treatment in children and adolescents receiving chemotherapy for early-stage primary lymphoma of bone. RESULTS: From 1983 to 1997, 31 patients with localized PLB were entered onto POG studies of early-stage non-Hodgkin's lymphoma (NHL). Between 1983 and 1986, seven patients were treated with 8 months of chemotherapy with irradiation (XRT) of the primary site. After 1986, patients were treated without XRT; four received 8 months of chemotherapy, and 20 received 9 weeks of chemotherapy. Primary sites were the femur (nine), tibia (eight), mandible (five), mastoid (one), maxilla (one), zygomatic arch (one), rib (one), clavicle (one), scapula (one), ulna (one), talus (one), and calcaneous (one). Histologic classification revealed 21 cases of large cell lymphoma, five cases of lymphoblastic lymphoma, two cases of small, noncleaved-cell lymphoma, and three cases of NHL that could not be classified further. One patient relapsed at a distant site 22 months after completion of therapy. There have been no deaths. CONCLUSION: Localized PLB is curable in most children and adolescents with a 9-week chemotherapy regimen of modest intensity, and radiotherapy is an unnecessary adjunct.  (+info)

*William Coley

Coley, William (1949). Neoplasms of Bone. New York: Medical Book Department of Harper & Brothers. pp. 565-570.. ... McCarthy, Edward F., MD, "The Toxins of William B. Coley and the Treatment of Bone and Soft-Tissue Sarcomas". Iowa Orthopedic ... William Bradley Coley (January 12, 1862 - April 16, 1936) was an American bone surgeon and cancer researcher best known for his ... McCarthy, Edward (2006). "The Toxins of William B. Coley and the Treatment of Bone and Soft-Tissue Sarcomas". The Iowa ...

*Kostniakomięsak, wolna encyklopedia

Altered expression of cell cycle regulatory proteins in benign and malignant bone and soft tissue neoplasms. „In Vivo". 21 (5 ... Bone Cancer Version 2.2016. „NCCN", 2016. *PG. Casali, JY. Blay, A. Bertuzzi, S. Bielack i inni. Bone sarcomas: ESMO Clinical ... Osteosarcoma in Paget's disease of bone. „J Bone Miner Res". 21 Suppl 2, s. P58-63, Dec 2006. DOI: 10.1359/jbmr.06s211. PMID: ... a b c d e Andrew L. Folpe, Carrie Y. Inwards: Bone and Soft Tissue Pathology: A Volume in the Foundations in Diagnostic ...

*Myeloid tissue

Myeloid neoplasms always concern bone marrow cell lineage and are related to hematopoietic cells. Myeloid tissue can also be ... Myeloid tissue, in the bone marrow sense of the word myeloid (myelo- + -oid), is tissue of bone marrow, of bone marrow cell ... Yuan J, Nguyen CK, Liu X, Kanellopoulou C, Muljo SA (2012). "Lin28b reprograms adult bone marrow hematopoietic progenitors to ... lineage, or resembling bone marrow, and myelogenous tissue (myelo- + -genous) is any tissue of, or arising from, bone marrow; ...

*Miriam Posner Finkel

Effect of Sr90 Upon Life Span and Neoplasms of Bone and the Blood-forming Tissues. Miriam P. Finkel, Birute O. Biskis, and ... Delayed effects of bone-seeking radionuclides (Ed. Mays, C.W., et al.). 417. Finkel, M. P., Biskis, B. O., & Jinkins, P. B. ( ... Finkel, M. P., Biskis, B. O., & Scribner, G. M. (1958). The influence of strontium-90 upon life span and neoplasms of mice (No ... 1960). Illinois bone tumor death certificate study. Annual report-Division of Biological and Medical Research. Argonne National ...

*Osteoblastoma

... is an uncommon osteoid tissue-forming primary neoplasm of the bone. It has clinical and histologic manifestations ... In the US, Osteoblastomas account for only 0.5-2% of all primary bone tumors and only 14% of benign bone tumors making it a ... Bone scintigraphy (bone scan) demonstrates abnormal radiotracer accumulation at the affected site, substantiating clinical ... The long tubular bones are another common site of involvement, with a lower extremity preponderance. Osteoblastoma of the long ...

*Myeloproliferative neoplasm

The myeloproliferative neoplasms (MPNs), previously myeloproliferative diseases (MPDs), are a group of diseases of the bone ... Although not a malignant neoplasm like other cancers, MPNs are classified within the hematological neoplasms. There are four ... According to the WHO Classification of Hematopoietic and Lymphoid Neoplasms 2008 myeloproliferative neoplasms are divided into ... All MPNs arise from precursors of the myeloid lineages in the bone marrow. The lymphoid lineage may produce similar diseases, ...

*Nodular fasciitis

USP6-induced neoplasms: the biologic spectrum of aneurysmal bone cyst and nodular fasciitis. Hum Pathol. 2013 Jun 11. doi:pii: ...

*Acute myelomonocytic leukemia

Acute myeloblastic leukemia (AML) is a group of malignant bone marrow neoplasms of myeloid precursors of white blood cells. ... Diagnostic methods include blood analysis, bone marrow aspirate for cytochemical, immunological and cytogeneticalanalysis, and ... Treatment includes intensive multidrug chemotherapy and in selected cases allogeneic bone marrow transplantation. Nevertheless ...

*Osteosarcoma

Overall survival prognosis is about 30%. Deaths due to malignant neoplasms of the bones and joints account for an unknown ... The tumor causes a great deal of pain, and can even lead to fracture of the affected bone. As with human osteosarcoma, bone ... Sometimes a sudden fracture is the first symptom, because affected bone is not as strong as normal bone and may fracture ... Large doses of Sr-90 emission from nuclear reactor, nicknamed bone seeker increases the risk of bone cancer and leukemia in ...

*Subcutaneous emphysema

It may also occur with fractures of the facial bones, neoplasms, during asthma attacks, when the Heimlich maneuver is used, and ...

*Myeloproliferative neoplasm

The myeloproliferative neoplasms (MPNs), previously myeloproliferative diseases (MPDs), are a group of diseases of the bone ... Although a malignant neoplasm like other cancers, MPNs are classified within the hematological neoplasms. There are four main ... According to the WHO Classification of Hematopoietic and Lymphoid Neoplasms 2008 myeloproliferative neoplasms are divided into ... All MPNs arise from precursors of the myeloid lineages in the bone marrow. The lymphoid lineage may produce similar diseases, ...

*Nonossifying fibroma

However, it is controversial whether it represents a true neoplasm or rather a developmental disorder of growing bone. ... They originate from the growth plate, and are located in adjacent parts of the metaphysis and diaphysis of long bones, most ... No treatment is needed in asymptomatic patients and spontaneous remission with replacement by bone tissue is to be expected. ... A nonossifying fibroma (also called fibroxanthoma) is a common benign bone tumor in children and adolescents. ...

*Oncogenic osteomalacia

A phosphaturic mesenchymal tumor is an extremely rare benign neoplasm of soft tissue and bone that inappropriately produces ... Rowe, PS; de Zoysa, PA; Dong, R; Wang, HR; White, KE; Econs, MJ; Oudet, CL (Jul 2000). "MEPE, a new gene expressed in bone ... Adult patients have worsening myalgias, bone pains and fatigue which are followed by recurrent fractures. Children present with ... Jun 2007). "Cinacalcet in the management of tumor-induced osteomalacia". Journal of Bone and Mineral Research. 22 (6): 931-37. ...

*Giant-cell carcinoma of the lung

Occasionally, a bone metastasis of a GCCL could potentially be mistaken for a primary giant-cell tumor of bone - interestingly ... Spivach A, Borea B, Bertoli G, Daris G (July 1976). "[Primary lung neoplasm of rare incidence: giant cell carcinoma]". Minerva ... Pai SB, Lalitha RM, Prasad K, Rao SG, Harish K (September 2005). "Giant cell tumor of the temporal bone-a case report". BMC Ear ... The new paradigm recognizes that lung cancers are a large and extremely heterogeneous family of malignant neoplasms, with over ...

*Simpson-Golabi-Behmel syndrome

Macrosomia Macroglossia Advanced bone age Organomegaly Neonatal hypoglycemia Neoplasms Congenital diaphragmatic hernia (CDH) " ... One of the most noted features of OGS is the increased risk of neoplasms in certain OGSs. SGBS in particular has been found to ... Limb patterning and skeletal development may also go awry when GCP3 mutations inhibit regulations of responses to bone ...

*List of MeSH codes (C04)

... tracheal neoplasms MeSH C04.588.448.200 --- bone marrow neoplasms MeSH C04.588.531.500 --- mammary neoplasms, experimental MeSH ... nose neoplasms MeSH C04.588.149.721.656 --- orbital neoplasms MeSH C04.588.149.721.828 --- skull base neoplasms MeSH C04.588. ... anal gland neoplasms MeSH C04.588.274.476.411.445 --- duodenal neoplasms MeSH C04.588.274.476.411.501 --- ileal neoplasms MeSH ... femoral neoplasms MeSH C04.588.149.721 --- skull neoplasms MeSH C04.588.149.721.450 --- jaw neoplasms MeSH C04.588.149.721. ...

*List of MeSH codes (C15)

... bone marrow neoplasms MeSH C15.378.420.155 --- anemia, sickle cell MeSH C15.378.420.155.440 --- hemoglobin sc disease MeSH ... bone marrow neoplasms MeSH C15.378.190.625 --- myelodysplastic syndromes MeSH C15.378.190.625.062 --- anemia, refractory MeSH ... splenic neoplasms MeSH C15.604.744.742 --- splenic rupture MeSH C15.604.744.742.500 --- splenosis MeSH C15.604.744.909 --- ...

*Brain tumor

The skull bone structure can also be subject to a neoplasm that by its very nature reduces the volume of the intracranial ... Neoplasms will often show as differently colored masses (also referred to as processes) in CT or MRI results. ... "CNS and Miscellaneous Intracranial and Intraspinal Neoplasms" (PDF). SEER Pediatric Monograph. National Cancer Institute. pp. ... More generally a neoplasm may cause release of metabolic end products (e.g., free radicals, altered electrolytes, ...

*Brain tumor

The skull bone structure can also be subject to a neoplasm that by its very nature reduces the volume of the intracranial ... "CNS and Miscellaneous Intracranial and Intraspinal Neoplasms" (PDF). SEER Pediatric Monograph. National Cancer Institute. pp. ... More generally a neoplasm may cause release of metabolic end products (e.g., free radicals, altered electrolytes, ... Due to the BBB, cancerous cells of a primary neoplasm cannot enter the bloodstream and get carried to another location in the ...

*Juvenile active ossifying fibroma

A juvenile active ossifying fibroma is a benign fibro-osseous neoplasm composed of mixture of stroma and bone characterized by ... MRI shows a variable finding depending on T1 or T2 weighted images, dependent on the amount of bone to fibrous connective ... Many times the curved-shaped bone fragments have a collagenous rim around them. Ossicles may fuse to form much large ... When performing imaging studies, bone windows in computed tomography studies are the best. The lesion is usually identified as ...

*Orthopedic oncologist

... will learn in depth about the pathology and treatment of various forms of primary benign and malignant neoplasms of the bones ... to the bones, which is much more common; these specialists deal mostly with primary bone tumors). The physician will study ... Due to the relative rarity of primary bone tumor in relation to other forms of cancer, there are fewer than two hundred ... it is advisable when confronted with primary malignancy of the bone to seek out the treatment of an orthopedic oncologist, due ...

*C40

... a malignant neoplasm of bone and articular cartilage of limbs ICD-10 code. ...

*Chondroblastoma

The work of Aigner et al suggests that chondroblastoma should be reclassified as a bone-forming neoplasm versus a cartilaginous ... "Chondroblastoma of Bone." The Journal of Bone and Joint Surgery 82A.8 (2000): 1140-1145. Web. 6 Dec. 2015. Kurt, Ann-Marie, et ... However, local recurrence for long bone lesions is around 10%, with chondroblastoma in flat bones having higher recurrence and ... locally aggressive bone tumor that typically affects the epiphyses or apophyses of long bones. It is thought to arise from an ...

*Bone tumor

Some benign tumors are not true neoplasms, but rather, represent hamartomas, namely the osteochondroma. The most common ... Stage 1A bone cancer Stage 1B bone cancer Stage 2A bone cancer Stage 2B bone cancer Stage 3 bone cancer Since, by definition, ... A bone tumor (also spelled bone tumour) is a neoplastic growth of tissue in bone. Abnormal growths found in the bone can be ... giant cell tumor of bone, aneurysmal bone cyst, and fibrous dysplasia of bone. Malignant primary bone tumors include ...

*Route of administration

intraocular, into the eye, e.g., some medications for glaucoma or eye neoplasms intraosseous infusion (into the bone marrow) is ... Recreationally the colloquial term 'boning' is used. intraperitoneal, (infusion or injection into the peritoneum) e.g. ... in effect, an indirect intravenous access because the bone marrow drains directly into the venous system. This route is ...

*Biphenotypic sinonasal sarcoma

Infiltrative, highly cellular spindled cell neoplasm that is poorly circumscribed and unencapsulated. Bone destruction or ... Definitions A low-grade spindle cell neoplasm of the sinonasal tract associated with overlying respiratory epithelium and ...

*Plasma cell

Recently they have been shown to reside for much longer periods in the bone marrow as long-lived plasma cells (LLPC). They ... Plasmacytoma, multiple myeloma, Waldenström macroglobulinemia and plasma cell leukemia are malignant neoplasms ("cancer") of ... After leaving the bone marrow, the B cell acts as an antigen presenting cell (APC) and internalizes offending antigens, which ... Plasma cells originate in the bone marrow; B cells differentiate into plasma cells that produce antibody molecules closely ...

*Aneurysmal bone cyst

... , abbreviated ABC, is an osteolytic bone neoplasm characterized by several sponge-like blood or serum ... Intermediate magnification micrograph of an aneurysmal bone cyst Simple bone cyst (SBC) Giant cell tumor of bone Traumatic bone ... Aneurysmal bone cysts may be intraosseous, staying inside of the bone marrow. Or they may be extraosseous, developing on the ... The lesion may arise de novo or may arise secondarily within a pre-existing bone tumor, because the abnormal bone causes ...
From the large reduction in tumor burden brought about by doxycycline, it appears more likely that the effectiveness relies on the properties of doxycycline as an inhibitor of tumor cell proliferation and less on its effect as a MMP inhibitor, because only a relative modest decrease in bone resorption was observed. Other osteolytic bone metastasis models, such as the one using orthotopic injections of 4T1 mouse mammary tumor cells (20) , will be examined in future studies to confirm our data obtained with the MDA-MB-231 cells. Our results suggest that doxycycline may be useful not only for the treatment of osteolytic but also for the treatment of osteoblastic bone metastasis. However, this remains to be determined using animal models specific for osteoblastic bone metastasis, such as the MCF-7 human breast cancer cell model (20) . The mechanism of action of doxycycline is very different from that of the bisphosphonate family of drugs that are used as therapeutic agents in clinical disorders ...
Q: My friend is only 16 but he was just diagnosed with cancer in his leg bone. Is this common?A: There are many cancers that can metastasize to the bones (so these are not primary bone cancers), but there are also some primary bone cancers that arise directly from cancerous bone cells. Osteosarcoma (OS) is the most common primary bone cancer, although overall it is a rare cancer representing only about 1 percent of all cancers diagnosed in the U.S. There are few than 1,000 new cases of OS
Q: My friend is only 16 but he was just diagnosed with cancer in his leg bone. Is this common?A: There are many cancers that can metastasize to the bones (so these are not primary bone cancers), but there are also some primary bone cancers that arise directly from cancerous bone cells. Osteosarcoma (OS) is the most common primary bone cancer, although overall it is a rare cancer representing only about 1 percent of all cancers diagnosed in the U.S. There are few than 1,000 new cases of OS
Research Report on EMEA (Europe, Middle East and Africa) Metastatic Bone Tumor Treatment Market Report 2017. The Report includes market price, demand, trends, size, Share, Growth, Forecast, Analysis & Overview.
Recent studies have contributed to the enhancement of clinical and molecular knowledge on bone lymphomas, a group of rare malignancies with particular characteristics. Nevertheless, several questions remain unanswered and the level of evidence supporting some diagnostic and therapeutic decisions remains low. Currently, three different forms of bone lymphomas can be distinguished: the primary bone lymphoma, consisting of a single bone lesion with or without regional lymphadenopathies; the polyostotic lymphoma, consisting of multifocal disease exclusively involving the skeleton; and the disseminated lymphoma with secondary infiltration of the skeleton. The first two forms exhibit a good prognosis, requiring treatments similar to those commonly used for nodal lymphomas of the same category, but several issues regarding the role of surgery and local control of the disease, the sequence of treatment, radiation volumes and doses, management of pathological fractures and prevention of late sequelae deserve
Tumor-induced bone disease is common among patients with advanced solid cancers, especially those with breast, prostate, and lung malignancies. The tendency of these cancers to metastasize to bone and induce bone destruction is, in part, due to alterations in integrin expression and signaling. Substantial evidence from preclinical studies shows that increased expression of integrin αvβ3 in tumor cells promotes the metastatic and bone-invasive phenotype. Integrin αvβ3 mediates cell adhesion to several extracellular matrix proteins in the bone microenvironment which is necessary for tumor cell colonization as well as the transmission of mechanical signals for tumor progression. This review will discuss the αvβ3 integrin receptor in the context of tumor-induced bone disease. Specifically, the focus will be the role of αvβ3 in modulating cancer metastasis to bone and tumor cell response to the bone microenvironment, including downstream signaling pathways that contribute to tumor-induced osteolysis.
In this case-based interview, oncologist Dan George, MD, discusses the management of a patient who develops prostate cancer bone metastases. Radiologist Rajan Gupta, MD, and radiation oncologist Glen Gejerman, MD, share viewpoints on the use of imaging and bone-targeted therapy for this patient.
TY - JOUR. T1 - Clinical usefulness of bisphosphonates in oncology. T2 - Treatment of bone metastases, antitumoral activity and effect on bone resorption markers. AU - Verì, A.. AU - DAndrea, M. R.. AU - Bonginelli, P.. AU - Gasparini, Giampietro. PY - 2007/1. Y1 - 2007/1. N2 - The present article overviews the role of bisphosphonates for the treatment and prevention of bone metastases and their antiangiogenic effects and antitumoral activity. The skeleton is a frequent and clinically relevant site of metastasis in cancer patients. The major events related to bone metastases include bone pain, bone loss, hypercalcemia, spinal cord compression, and fractures. On the basis of their radiographic features, bone metastases are classified as osteoblastic, osteoclastic, or mixed. The primary goals of treatment of bone metastases are reduction of the risk of pathological fractures and other skeletal-related events, and pain control. Bisphosphonates are used to prevent pathological fractures by ...
Bone metastasis is a complex process that needs to be better understood in order to help clinicians prevent and treat it. Xenografts using patient-derived material (PDX) rather than cancer cell lines are a novel approach that guarantees more clinically realistic results. A primary culture of bone metastasis derived from a 67-year-old patient with breast cancer was cultured and then injected into zebrafish (ZF) embryos to study its metastatic potential. In vivo behavior and results of gene expression analyses of the primary culture were compared with those of cancer cell lines with different metastatic potential (MCF7 and MDA-MB-231). The MCF7 cell line, which has the same hormonal receptor status as the bone metastasis primary culture, did not survive in the in vivo model. Conversely, MDA-MB-231 disseminated and colonized different parts of the ZF, including caudal hematopoietic tissues (CHT), revealing a migratory phenotype. Primary culture cells disseminated and in later stages extravasated from the
Project summary Breast cancer frequently metastasizes to be where it leads to osteolysis and poor clinical prognosis; however, the role of hydroxyapatite nanocrystals (HA, the mineral component of bone) in this process remains unclear due, in part, to the lack of appropriate culture models. The overall goal of these studies is to design a mineralized 3-D tumor model that captures the intrinsic 3-D cell-microenvironment interactions within bone- metastatic niches and nanostructural alterations of HA that may occur due to disease and aging. Specifically, we will develop porous poly (lactide-co-glycolide) (PLG) scaffolds that incorporate HA nanoparticles of defined physicochemical characteristics and assess the applicability and relevance of this 3-D tumor model to test the functional relationships between HA and osteolytic bone metastasis. This work will be accomplished in three specific aims: In Aim 1, we will develop the 3-D matrices by synthesizing monodispersed nanoparticles of HA with ...
Project summary Breast cancer frequently metastasizes to be where it leads to osteolysis and poor clinical prognosis; however, the role of hydroxyapatite nanocrystals (HA, the mineral component of bone) in this process remains unclear due, in part, to the lack of appropriate culture models. The overall goal of these studies is to design a mineralized 3-D tumor model that captures the intrinsic 3-D cell-microenvironment interactions within bone- metastatic niches and nanostructural alterations of HA that may occur due to disease and aging. Specifically, we will develop porous poly (lactide-co-glycolide) (PLG) scaffolds that incorporate HA nanoparticles of defined physicochemical characteristics and assess the applicability and relevance of this 3-D tumor model to test the functional relationships between HA and osteolytic bone metastasis. This work will be accomplished in three specific aims: In Aim 1, we will develop the 3-D matrices by synthesizing monodispersed nanoparticles of HA with ...
Primary bone cancer starts in bone or cartilage while metastatic bone cancers begin elsewhere in the body and spread to bones. Learn about how they differ.
Bone metastases are frequently one of the first signs of disseminated disease in cancer patients. Skeletal complications due to metastatic disease include (severe) bone pain, impaired mobility, spinal cord compression, pathological fractures, and hypercalcemia. Radiotherapy and surgery are the options for the specific local treatment of bone metastases. Chemotherapy, hormonotherapy and bisphosphonates are systemic weapons used in the treatment of bone metastases with or without hypercalcemia. Cancers with propensity to metastasize to bones such as breast, prostate, lung and myeloma may possess the capacity to interact with osteoclasts. Osteoclasts are specialized bone cells, which erode mineralized bone by secreting acids and lysosomal enzymes. In normal bone remodeling, osteoclastic bone resorption is coupled to and is in equilibrium with osteoblastic bone formation. The lytic bone destruction associated with malignant bone metastases develops because tumor cells synthesize and release soluble ...
Recurring breast cancer can sometimes spread to your bones. A long-term study conducted by the by the Hacettepe University Institute of Oncology in Turkey on 141 women with breast cancer and bone metastasis found that the median survival rate was two years, according to ascopubs.org.
Ablative treatment of metastatic bone tumors and relief of pain associated with metastatic bone tumors is achieved by heat ablation of the bone tumor or tissue near the bone tumor by an ablation probe. In one form the probe is an electrode coupled to a high frequency power supply to provide ablative heating of tissue proximate to an electrode that is placed in or near the bone tumor. Cooling of the electrode by fluid circulation from a cooling apparatus outside the patients body may be used to enlarge the region of high frequency heating around the electrode. Image guidance of the electrode placement may be monitored by an imaging device. Tracking of the electrode by an image-guided navigator helps in placement of the electrode with respect to the configuration of the bone and bone metastasis. A set of tools accommodates biopsy and various shapes of electrodes according to clinical requirements. Several forms of electrodes, energy delivery and cooling apparatus and methods accommodate the specific
Results of the trial were presented today (Sunday) at the 2011 European Multidisciplinary Cancer Congress [1].. Professor Peter Hoskin, consultant clinical oncologist at the Mount Vernon Cancer Centre, Northwood, UK, and Professor of Clinical Oncology at University College, London, and colleagues, randomised 470 patients with primary prostate cancer and painful bone metastases to receive either a single dose of radiation or a single intravenous infusion of the bisphosphonate ibandronate (IB). Patients reported their primary site of pain at entry into the trial, and then at four, eight, twelve, 26 and 52 weeks after treatment.. Those who had not responded to the first treatment at four weeks crossed over to the alternative therapy and received their second treatment no later than week eight. Pain levels were measured at four and twelve weeks by examining analgesic use, using a combination of scoring via the WHO pain ladder [2] and the Mercadante method, which defines analgesic use in morphine ...
TY - JOUR. T1 - A csontáttétképzodés molekuláris alapjai és célzott terápiája. AU - Tímár, J.. PY - 2010/3/1. Y1 - 2010/3/1. N2 - Formation of bone metastasis is a hallmark of the progression of several solid cancers, providing example for the organ specificity of the process. Bone metastasis may result in both venous and arterial dissemination. Though the molecular basis of the lytic and plastic bone metastasis formation is different, in reality these organ metastases represent a mixture of the two processes. The basis of bone metastasis formation is the activation of osteoclasts and the resulting bone resorption, initiating a vicious circle by activating the initiator cancer cell. The discovery of osteoclast-bone matrix interaction inhibitor bisphosphonates revolutionized the therapy of bone metastasis. Clarifying the molecular pathways involved in bone metastasis formation identified osteoclast differentiation as another feasible target. This process is under control of the TNF ...
TY - JOUR. T1 - The Characteristics of Bone Metastasis in Patients with Colorectal Cancer. T2 - A Long-Term Report from a Single Institution. AU - Baek, Se Jin. AU - Hur, Hyuk. AU - Min, Byung Soh. AU - Baik, Seung Hyuk. AU - Lee, Kang Young. AU - Kim, Namkyu. PY - 2016/4/1. Y1 - 2016/4/1. N2 - Background: Bone metastasis in patients with colorectal cancer (CRC) is very rare, and data are extremely lacking. We aimed to evaluate the characteristics of bone metastasis in patients with CRC. Materials and methods: We performed a chart review of 63 patients (1.1 %) with bone metastasis among 5479 patients who underwent surgery for CRC. Results: Most patients were stage 3 (17.5 %) or 4 (73.0 %), and 32 patients (50.8 %) were diagnosed with bone metastasis at initial diagnoses of CRC. Thirty-one patients developed bone metastasis during the follow-up period with median 10.1-month interval. PET-CT was most frequently used for the diagnosis of bone metastasis (71.4 %), and the spine was the most commonly ...
24 yo man with right-sided lower posterior chest/rib pain for 4-6 months, increases with deep inspiration. He denies history of trauma.
Data & statistics on Bone Metastases Therapy: Bone metastases from hormone‐resistant prostate cancer., Kinetic analysis of 18F-fluoride PET images can differentiate osteoblastic and osteolytic lesions in breast cancer metastases. The authors concluded that fluoride flux and transport can be accurately and independently measured for bone metastases and normal vertebrae., Inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer,
DR. K. MSK cases has some excellent information to share with technologists!! make some time to visit this site. Below is an example: Primary lymphoma of the bone accounts for approximately 3% of malignant bone neoplasms and comprises less than 5% of all extranodal non-Hodgkins lymphomas. Diagnosis of primary bone lymphoma includes initial involvement of a single…
This booklet is about primary bone cancer. It covers what it is, the causes, symptoms, how it is diagnosed, treatments and clinical trials.
Primary malignant bone tumours, osteosarcomas, and Ewing sarcomas are rare diseases which occur mainly in adolescents and young adults. With the current therapies, some patients remain very difficult to treat, such as tumour with poor histological response to preoperative CT (or large initial tumour volume for Ewing sarcomas not operated), patients with multiple metastases at or those who relapsed. In order to develop new therapies against these rare tumours, we need to unveil the key driving factors and molecular abnormalities behind the malignant characteristics and to broaden our understanding of the phenomena sustaining the metastatic phenotype and treatment resistance in these tumours. In this paper, starting with the biology of these tumours, we will discuss potential therapeutic targets aimed at increasing local tumour control, limiting metastatic spread, and finally improving patient survival.
Bone metastasis, or the development of secondary tumors within the bone of cancer patients, is a debilitating and incurable disease. Despite its morbidity, the biology of bone metastasis represents one of the most complex and intriguing of all oncogenic processes. This complexity derives from the intricately organized bone microenvironment in which the various stages of hematopoiesis, osteogenesis, and osteolysis are jointly regulated but spatially restricted. Disseminated tumor cells (DTCs) from various common malignancies such as breast, prostate, lung, and kidney cancers or myeloma are uniquely primed to subvert these endogenous bone stromal elements to grow into pathological osteolytic or osteoblastic lesions ...
Metastatic bone disease arises from the spread of certain cancers to the skeletal system. The sarcoma care team assesses impending fracture and coordinates care.
Background The skeleton is the most common site of prostate cancer metastasis, which often results in osteoblastic lesions. type I receptor kinase or a pan TGF binding protein (BGERII) also decreased bone tumor growth and osteoblastic bone formation after seven weeks of treatment. Conclusions Our results for the first time indicate that blockade of TGF signaling in the PacMetUT1 model significantly inhibits osteoblastic bone formation and tumor incidence. Thus, TGF signaling pathway may be a viable target for the prevention and treatment of prostate cancer-induced bone metastasis. [10]. The expression of PTHrP in prostate cancer cells can also be induced by TGF, resulting in PTHrP-induced bone resorption [10, 11]. Contrary to this, TGF1 has also been shown to enhance the expression of osteoprotegerin (OPG), which inhibits osteoclasts, thereby regulating bone turnover [12, 13]. Thus, the UK-383367 UK-383367 part of TGF signaling in prostate malignancy caused bone tissue metastasis appears ill ...
Pharmatest Services Ltd has developed in collaboration with Taconic Biosciences a novel humanized mouse model of tumor growth in bone that can be used for testing immunotherapies. Testing compound efficacy in bone microenvironment should decrease substantially the very high number of cancer drugs currently failing in clinical trials due to poor efficacy.. Pharmatest Services Ltd (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. In oncology Pharmatest has special expertise in models of bone metastasis. Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services.. Bone metastases are common and increase mortality in many cancers such as breast, prostate and lung cancers, and multiple myeloma. Bone microenvironment changes tumor properties and induces drug resistance. Thus, showing compound efficacy in the commonly used ...
Pregnancy complicated by Non Hodgkin lymphoma (NHL) is rare, about 100 cases have been reported. We will describe the case of a multifocal bone lymphoma revealed by a left hyperalgetic and deficient cruralgia in a female in the second trimester of pregnancy.
The skeleton is the most common site of prostate cancer bone metastasis, and at present, there are no curable treatments for these patients. To further understand what stimulates tumor cell growth in the bone microenvironment and to find suitable therapies, reliable model systems are needed. For this purpose, we have developed an in vitro co-culture system that can be used to study interactions between tumor cells and murine calvarial bones. To validate the model, we measured the release of collagen fragments and monitored changes in expression levels of genes normally expressed during active bone remodeling.. One of the major reasons why prostate cancer cells colonize bone is the abundance of tumor-stimulating factors, such as insulin-like growth factors (IGFs), present in this milieu. We found that the IGF-1 receptor (IGF-1R) was one of the most highly activated receptor tyrosine kinases in tumor cell lines stimulated with bone conditioned media. Since IGF-1 is known to be a strong survival ...
Bone sarcomas are primary bone tumors, which means that they start in the bones. They are usually found in children. Osteosarcoma, the most common type of primary bone cancer, usually occurs in the thigh, upper arm or shin.
Bone metastasis is a common event in advanced cancers such as prostate, breast, lung, and renal cancers. Radiation therapy has been widely used for bone metastasis. However, it remains a challenging therapy because no radiation therapeutic guidelines, including radiation dose, radiation field, and fractionation, for patients with bone metastasis have been established. Many randomized controlled trials for bone metastasis have been carried out. They showed no significant difference in pain relief with a short course of radiation therapy such as 8 Gy/1 Fr and 20 Gy/5 Fr or with a long course of radiation therapy such as 30 Gy/10 Fr, 37.5 Gy/15 Fr, and 40 Gy/20 Fr. Toxicity rates with short and long courses were also the same. Recurrence rate at 2 years, however, was significantly higher in patients irradiated with a short course than in patients irradiated with a long course. Those trials also showed that response rate is affected by patients age, performance state, tumor type, pathological state, number
The five-year survival rate for primary bone cancers is ~ 70% while almost all cases of secondary metastatic bone cancer are terminal. Hypoxia, the deficiency of oxygen which occurs as the rate of tumour growth exceeds the supply of vascularisation, is a key promoter of tumour progression. Hypoxia-driven effects in the primary tumour are wide ranging including changes in gene expression, dysregulation of signalling pathways, resistance to chemotherapy, neovascularisation, increased tumour cell proliferation and migration. Pagets seed and soil theory states that for a metastasising tumour cell the seed it requires the correct microenvironment soil to colonise. Why and how metastasising tumour cells colonise the bone is a complex and intriguing problem. However, once present tumour cells are able to disrupt bone homeostasis through increasing osteoclast activity and downregulating osteoblast function. Osteoclast resorption releases growth factors from the bone matrix that subsequently contribute to
Bone tumors - MedHelps Bone tumors Center for Information, Symptoms, Resources, Treatments and Tools for Bone tumors. Find Bone tumors information, treatments for Bone tumors and Bone tumors symptoms.
Updates for oncologists on bone metastases and skeletal-related events from breast cancer and prostate cancer, including treatment with RANKL inhibitor and more.
Laminin binding integrin receptors are key mediators of epithelial cell migration and tumor metastasis. Recent studies have demonstrated a role for the alpha 6 integrin (ITGA6/CD49f) in maintaining stem cell compartments within normal bone marrow and in residency of tumors metastatic to bone. In this study, we tested a function-blocking antibody specific for ITGA6, called J8H, to determine if pre-existing cancer lesions in bone could be slowed and/or animal survival improved. Human prostate tumors were established by intracardiac injection into male severe combined immunodeficient (SCID) mice and treatment with J8H antibody was initiated after one week. Tumor progression was monitored by micro computed tomography (CT) imaging of skeletal lesions. Animals that received weekly injections of the anti-ITGA6 antibody showed radiographic progression in only 40% of osseous tumors (femur or tibia), compared to control animals, where 80% of the lesions (femur or tibia) showed progression at 5 weeks. ...
Bone cancer can originate either in the bone or when another cancer spreads to the bone. Most common types of bone cancer are osteosarcoma, Ewings sarcoma, and chondrosarcoma. Depending upon the stage of bone cancer, doctor may recommend various tre
Bone metastasis is not typically a positive diagnosis. A 2013 article in the Yonsei Medical Journal stated the survival estimate for breast cancer patients with bone-only metastasis after 10 years at...
Primary bone cancer occurs when the cancer originates in your bones, which is very rare. Secondary bone cancer refers to cancer that has spread to the bone from another part of the body.
Bone is the most common site of neoplastic metastasis and Non-Small Cell Lung Carcinoma (NSCLC) frequently metastasizes at the bone level, frequently ..
Osteosarcoma, or bone cancer, is an uncommonly diagnosed cancer, making up roughly 1 percent of all cancers in American each year. Most cases of bone cancer are tumors spread from a nearby organ, or metastasized. Doctor use treatments, such as chemotherapy, surgery and radiation to treat bone cancer. But you can ...
Wife aged 76, Bone Cancer stage 4, cancer in spine,sternum,rib shoulder and maybe more. We.from breast cancer ten years.prior. Estimate time of survival please. First round of treatments, instance failed, radiation second time around. New chemicals.coming, the doctor says chemo. Possible length of survival I am wonder
It is true that in patients under 30 years a well-defined border means that we are dealing with a benign lesion, but in patients over 40 years metastases and multiple myeloma have to be included in the differential diagnosis. ...
It is true that in patients under 30 years a well-defined border means that we are dealing with a benign lesion, but in patients over 40 years metastases and multiple myeloma have to be included in the differential diagnosis. ...
It is true that in patients under 30 years a well-defined border means that we are dealing with a benign lesion, but in patients over 40 years metastases and multiple myeloma have to be included in the differential diagnosis. ...
This review will examine agents with potential activity in the palliation and treatment of skeletal metastases of prostate cancer, and will weigh the clinical-outcomes evidence for and against their broad use. 1
QUADRAMET® is an injectable radiopharmaceutical used for pain relief in cancer patients suffering from osteoblastic metastatic bone lesions. Read more.
Quadramet [Sm-153] is a radioactive material approved for use in the treatment of widespread bony metastases from cancer. It is given as an outpatient as an intravenous injection.
The outlook for bone cancer depends on factors such as your age, the type of bone cancer you have, how far the cancer has spread (the stage), and how likely it is to spread further (the grade). Generally, bone cancer is much easier to cure in otherwise healthy people whose cancer hasnt spread.. Overall, around 6 in every 10 people with bone cancer will live for at least 5 years from the time of their diagnosis, and many of these may be cured completely.. For more detailed statistics broken down by the different types of bone cancer, see the page on statistics and outlook for bone cancer on the Cancer Research UK website.. ...
To diagnose secondary bone cancer, the doctors first chart a course of curative action, take scans and come to a conclusion based on the results. Read more about the procedure of diagnosis.
Care guide for Bone Metastasis (Discharge Care). Includes: possible causes, signs and symptoms, standard treatment options and means of care and support.
Bone cancer has few symptoms. When my sister received her diagnosis, I learned a lot about the symptoms, treatments, and how to help a loved one cope with this condition.
Reduction of Risk Factors. While the genetic factor is a threat that is waiting to be triggered to develop Bone Cancer, the best owners can do to lessen the chance of its stimulation is to avoid carcinogens from entering the dogs body. The less amount of carcinogens there are in the body, the less chances of […]. ...
Whether you (or a loved one) are worried about developing bone cancer, have just been diagnosed, are going through treatment, or are trying to stay well after treatment, this detailed guide can help you find the answers you need.
What would be the point of running a test? If a dog shows clinical signs of lymphoma, you could pay the $120 for this blood test, or you could simply send in an aspirate of a swollen lymphnode. Not to mention the fact if a dog is showing clinical signs and you know its lymphoma all this test does is tell you that the dog definitely has some kind of cancer. I mean... weve had one bone cancer patient that looked like bone cancer at first, sent the rads in to a specialist the specialist said the dog had osteoporosis, treated with pain meds, rechecked in 3mos when the dog was getting worse and it was definitely bone cancer. So Im not really sure how I feel about this because I feel like theres already enough ways to diagnose cancer. I guess if your specialist is unsure about a lump or something you could run it, but again it doesnt tell you where the cancer is or what it is so you couldnt necessarily make a diagnoses off of the results because it just tells you the dog has it somewhere in the ...
What would be the point of running a test? If a dog shows clinical signs of lymphoma, you could pay the $120 for this blood test, or you could simply send in an aspirate of a swollen lymphnode. Not to mention the fact if a dog is showing clinical signs and you know its lymphoma all this test does is tell you that the dog definitely has some kind of cancer. I mean... weve had one bone cancer patient that looked like bone cancer at first, sent the rads in to a specialist the specialist said the dog had osteoporosis, treated with pain meds, rechecked in 3mos when the dog was getting worse and it was definitely bone cancer. So Im not really sure how I feel about this because I feel like theres already enough ways to diagnose cancer. I guess if your specialist is unsure about a lump or something you could run it, but again it doesnt tell you where the cancer is or what it is so you couldnt necessarily make a diagnoses off of the results because it just tells you the dog has it somewhere in the ...
Having cancer and dealing with treatment can be time-consuming and emotionally draining, but it can also be a time to look at your life in new ways.
If you seek to connect and present your product or service to an engaged oncology healthcare community, you have come to the right place. More information. ...
Background: Bone metastasis is a common complication of certain types of cancer, and unfortunately, it is still incurable to date. Immune system is a major defe
BackgroundOsteosarcoma is the most common pediatric malignant bone tumor, frequently surgically managed with limb salvage rather than amputation. Local recurrences are seen in up to 9% of osteosarcoma patients, with CT and MRI imaging often limited by metal artifacts.ObjectiveTo describe the [F-18]2-fluoro-2-deoxyglucose (FDG) PET/CT appearance of local osteosarcoma recurrences with correlation to findings on other imaging modalities.Materials and methodsA retrospective review of pediatric osteosarcoma patients imaged with FDG PET/CT was performed in patients with pathologically proven local recurrences. FDG PET/CT findings were reviewed and correlated with available comparison imaging studies.ResultsTen local osteosarcoma recurrences in eight pediatric osteosarcoma patients were imaged with FDG PET/CT. All eight patients had a local recurrence after limb salvage; two patients had a second local recurrence after amputation. All local recurrences were seen with FDG PET/CT, demonstrating solid (n=5) or
We will conduct a prospective trial to verify the validity of indices utilizing TGF-b1, NF-kB, PET/CT, and MRS for predicting response to neoadjuvant chemotherapy in osteosarcoma patients. We assume that changes in plasma TGF-b1 levels, PET/CT and magnetic resonance spectroscopy (MRS) findings during the period of neoadjuvant chemotherapy as well as the initial nuclear NF-kB expression status of tumor biopsy specimen either alone or in combination may predict a chemotherapeutic response determined by histopathologic necrosis fractions of tumors removed. To test this, we will obtain TGF-b1 levels, PET/CT and MRS findings at diagnosis and at follow-up (after first and second/third chemotherapy cycle). Tumor will then be removed. Chemotherapy regimen comprised of various combination of cisplatin, adriamycin, and high-dose methotrexate, ifosfamide, and etoposide. Indices derived from TGF-b1, PET/CT, MRS predicting greater than 90% necrosis fractions will be sought utilizing statistical methods ...
Osteosarcomas are the most common primary malignant bone tumor that occurs in children and adolescents, and they frequently occur around the knee. In the past, amputation or joint disarticulation was the standard of care. Currently, more than 90% of osteosarcoma resections are limb-sparing procedures because of advancements in chemotherapeutic regimens and three-dimensional imaging studies, including CT and MRI. In addition, joint-sparing surgery is possible in select patients. To preserve the joint structure for good limb function in patients with osteosarcoma, we have been performing epiphyseal or metaphyseal osteotomy and biologic reconstruction via frozen autograft treated with liquid nitrogen. Several advantages are expected with the use of the freezing technique. This strategy involves simple surgical technique without specialized devices. A perfect fit is achieved because the managed bone is the patients own and bone strength is maintained postoperatively. Satisfactory bone union and
Title: Bone Seeking Radiopharmaceuticals for Palliation of Pain in Cancer Patients with Osseous Metastases. VOLUME: 7 ISSUE: 4. Author(s): M.G.E.H. Lam, J.M.H. de Klerk, P.P. van Rijk and B.A. Zonnenberg. Affiliation:University Medical Center Utrecht, Department of Nuclear Medicine, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.. Keywords:Bone metastases, Radionuclide therapy, Pain palliation, Samarium-153-EDTMP, Rhenium-186-HEDP, Strontium-89-Chloride. Abstract: Many patients with cancer develop symptomatic skeletal metastases at an advanced stage of their disease. Skeletal metastases are often complicated by pain. They cause considerable morbidity and mortality. Besides analgesics, treatment options include external beam radiotherapy, bisphosphonates, chemotherapy, surgery and bone seeking radiopharmaceuticals. Pain palliation with bone seeking radiopharmaceuticals has proved to be an effective treatment modality in patients with metastatic bone pain. Radiopharmaceuticals bind to the bone ...
Osteosarcoma, a primary bone cancer. The osteosarcoma is one of the primary cancers of the bone, that is to say developed from bone cells, cartilage or fibrous tissue, as opposed to secondary cancers of the bone metastases that are of cancer in another organ. The osteosarcoma is primary bone cancer the most common, before the chondrosarcoma, Ewings sarcoma and multiple myeloma . Of unknown cause, osteosarcoma usually occurs in children and young adults, between 10 and 25 years. The bones are usually affected long bones near the knee or shoulder: tibia, femur and humerus. We traditionally distinguish two forms of osteosarcoma: one attacks the central part of the bone (medullary bone), the other in the peripheral zone of the bone, destroying the periosteum, the membrane that surrounds the bone and is responsible for its growth in thickness. You should also remember that osteosarcoma can spread through the bloodstream and invade the lungs causing pulmonary metastases.. The first signs of ...
Eight patients presented without any evidence of metastatic disease; 4 of them had advanced local disease, including large tumour mass with soft-tissue compromise, neurovascular encasement and pathological fracture. Limb salvage was performed in 2/8 patients who presented without metastatic disease, both of whom had a proximal tibial tumour, and underwent wide resection and megaprosthesis total knee replacement.. Three of the patients were older than expected for primary osteosarcoma, aged 40, 51 and 53 years, respectively. Two of these patients were HIV-1 infected; further research is being conducted to determine the causality, if any, between osteosarcoma and HIV-1 infection.. Discussion. Osteosarcoma is a primary malignant bone tumour that is characterised by the proliferation of malignant mesenchymal cells capable of the direct production of osteoid.3,4,6,9 The World Health Organizations histological classification further divides osteosarcoma into medullary and surface tumours, which are ...
LAUBSCHER, M; HELD, M e DUNN, RN. Primary bone tumours of the spine: Presentation, surgical treatment and outcome. SA orthop. j. [online]. 2015, vol.14, n.2, pp.22-28. ISSN 2309-8309. http://dx.doi.org/10.17159/2309-8309.. BACKGROUND: Primary bone tumours of the spine are a group of rare tumours that include both benign and malignant lesions. Resection is associated with a high morbidity rate. METHODS: We retrospectively reviewed all the primary bone tumours of the spine that were surgically treated at our unit between 2005 and 2012 (haematological malignancies were excluded. RESULTS: Fifteen cases were included that presented at a median age of 36 years (range 8 to 65 years). Pain was the most common presenting symptom. Three patients had significant neurological deficits at time of presentation and in two cases there was an improvement after surgery. The median delay in diagnosis was 7 months (range 1 to 36 months). A variety of surgical strategies was employed with the use of adjuvant radio- ...
TY - JOUR. T1 - Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. AU - Lussier, Danielle M.. AU - ONeill, Lauren. AU - Nieves, Lizbeth M.. AU - McAfee, Megan S.. AU - Holechek, Susan A.. AU - Collins, Andrea W.. AU - Dickman, Paul. AU - Jacobsen, Jeffrey. AU - Hingorani, Pooja. AU - Blattman, Joseph. PY - 2015/3/27. Y1 - 2015/3/27. N2 - Osteosarcoma is the most common bone cancer in children and adolescents. Although 70% of patients with localized disease are cured with chemotherapy and surgical resection, patients with metastatic osteosarcoma are typically refractory to treatment. Numerous lines of evidence suggest that cytotoxic T lymphocytes (CTLs) limit the development of metastatic osteosarcoma. We have investigated the role of PD-1, an inhibitory TNFR family protein expressed on CTLs, in limiting the efficacy of immune-mediated control of metastatic osteosarcoma. We show that human metastatic, but not primary, osteosarcoma tumors express a ...
The reciprocal interaction between cancer cells and the tissue-specific stroma is critical for primary and metastatic tumor growth progression. Prostate cancer cells colonize preferentially bone (osteotropism), where they alter the physiological balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption, and elicit prevalently an osteoblastic response (osteoinduction). The molecular cues provided by osteoblasts for the survival and growth of bone metastatic prostate cancer cells are largely unknown. We exploited the sufficient divergence between human and mouse RNA sequences together with redefinition of highly species-specific gene arrays by computer-aided and experimental exclusion of cross-hybridizing oligonucleotide probes. This strategy allowed the dissection of the stroma (mouse) from the cancer cell (human) transcriptome in bone metastasis xenograft models of human osteoinductive prostate cancer cells (VCaP and C4-2B). As a result, we generated the osteoblastic
Deregulation of microRNA (miRNA) transcript levels has been observed in many types of tumors including osteosarcoma. Molecular pathways regulated by differentially expressed miRNAs may contribute to the heterogeneous tumor behaviors observed in naturally occurring cancers. Thus, tumor-associated miRNA expression may provide informative biomarkers for disease outcome and metastatic potential in osteosarcoma patients. We showed previously that clusters of miRNAs at the 14q32 locus are downregulated in human osteosarcoma. Human and canine osteosarcoma patients samples with clinical follow-up data were used in this study. We used bioinformatics and comparative genomics approaches to identify miRNA based prognostic biomarkers in osteosarcoma. Kaplan-Meier survival curves and Whitney Mann U tests were conducted for validating the statistical significance. Here we show that an inverse correlation exists between aggressive tumor behavior (increased metastatic potential and accelerated time to death) and the
Ewings sarcoma: a primary bone cancer. Ewing sarcoma is one of the primary tumors of bone, that is to say that cancer cells originate from bone, and that are not met static cancer located elsewhere in another organ. Ewing sarcoma is unique in touch more often men than women. It also develops mainly in children between 10 and 15 years , more rarely in young adults up to age 25. Cancer cells usually reach the long bones like the femur and tibia. Thus Ewing sarcoma most often for the arms and legs, even though this cancer can affect any bone.. Bone cancer: what are the symptoms of Ewings sarcoma?. The symptoms are typically those of bone cancer: bone cancer is painful and swollen. Moreover, it is fragile and may break at the slightest shock. When the tumors grew, they can sometimes go up to affect the bone throughout its length. The diagnosis of Ewings sarcoma is based on the radiograph but also require a confirmatory biopsy. It depletes cells in the suspicious area for examination and to ...
Osteolytic bone metastases are frequent in patients with advanced cancer of the breast, lung, and (to a lesser extent) the prostate. Roentgenography, bone scintigraphy, and bone biopsies are commonly used for the early identification and follow-up of these conditions. These methods have though marked shortcomings as they are all static methods giving a picture of the current situation in bone but not telling about rate of changes taking place in bone. Metabolic bone markers have been shown to be a useful tool for monitoring metastatic bone activity.. It has been shown that there are two different pathways of bone resorption: the cathepsin K-mediated pathway, which is active during physiological resorption of bone, and the matrix metalloproteinase pathway, which functions mainly in pathological situations. ICTP specifically reflects matrix metalloproteinase-mediated pathological degradation of bone collagen (1, 2). ICTP is thus a highly specific marker of bone degradation in bone metastasis and ...
Fibro osseous lesions area diverse group of disorders characterized by replacement of normal archi- tecture of bone by a benign connective tissue matrix that displays various amount ofmineralizationin the form of woven bone or cementum. It includes developmental, reactive and neoplastic lesions. The different type of fibro-osseous lesions express a common clinical and radiological features. Soad- equate knowledge and clinical observationare necessary for proper interpretation and appropriate diagnosis of these lesions.becausemanagement of patients with fibro-osseous lesions are case specificandindividualized.The aim of this study was to analyse the clinical, radiological and histo- pathological characteristics of fibro osseous lesions andprovide a proper management system affect- ed by this type of lesions. Materials and methods:The retrospective study was performed in the Department of Oral & Maxillofacial surgery, Dhaka Dental College and Hospital, Dhaka, Bangladesh from a period of January ...
Osteosarcoma is a rare neoplasm that develops in bone tissue. Our osteosarcoma patients receive efficient, coordinated treatment from a multidisciplinary team of specialists that include pediatric ...
According to Orthobullets, the life expectancy for someone with metastatic bone cancer is about six months. However, WebMD points out that this depends largely on age of the patient and how far along...
MeSH-minor] Aged. Anti-Bacterial Agents / therapeutic use. Arthroplasty, Replacement, Knee / adverse effects. Debridement. Decision Making. Device Removal. Gram-Positive Bacterial Infections / drug therapy. Gram-Positive Bacterial Infections / surgery. Humans. Knee Prosthesis / adverse effects. Male. Mental Competency. Mental Disorders / diagnosis. Mental Disorders / psychology. Neoplasms, Unknown Primary / diagnosis. Prosthesis-Related Infections / drug therapy. Prosthesis-Related Infections / surgery. Recurrence. Suppuration. Treatment ...
Osteosarcoma is among the most frequently occurring primary bone tumors, primarily affecting adolescents and young adults. Despite improvements in osteosarcoma treatment, more specific molecular targets are needed as potential therapeutic options. One target of interest is α-Ca2+/calmodulin-dependent protein kinase II (α-CaMKII), a ubiquitous mediator of Ca2+-linked signaling, which has been shown to regulate tumor cell proliferation and differentiation. Here, we investigate the role of α-CaMKII in the growth and tumorigenicity of human osteosarcoma. We show that α-CaMKII is highly expressed in primary osteosarcoma tissue derived from 114 patients, and is expressed in varying levels in different human osteosarcoma (OS) cell lines [MG-63, N-methyl-N′-nitro-N-nitrosoguanidine (MNNG)/HOS, and 143B). To examine whether α-CaMKII regulates osteosarcoma tumorigenic properties, we genetically inhibited α-CaMKII in two osteosarcoma cell lines using two different α-CaMKII shRNAs delivered by ...
Osteosarcoma (OS) is the most common, non-hematopoietic, primary malignant bone tumor. OS is characterized by its aggressive local growth and systemic dissemination. Although combination of surgical operation and adjuvant chemotherapy greatly improved the prognosis, more than 20% of patients still cannot get long-term survival. Therefore, novel therapeutic approaches should be expected to be developed. Previously, we developed an OS mouse model by overexpressing c-MYC in bone marrow stromal cells derived from Ink4a/Arf knockout mice. We isolated highly tumorigenic cells (designated AXT cells) from tumors after serial transplantation. Inoculation of AXT cells into syngeneic C57BL/6 mice results in the development of lethal OS with metastatic lesions including lung, which pathologically and clinically mimics human osteoblastic osteosarcoma. To obtain the novel therapeutic agents for OS, we performed drug screening using existing drug collections and found that statins strongly suppressed AXT cell ...
In this study, we showed that TGF-β signaling in prostatic fibroblasts contributed to subsequent prostate cancer bone metastasis through paracrine interactions. Conditioned medium prepared from koPFs promoted the early development and growth of prostate cancer mixed bone lesions in the tibiae of mice. This effect was, in part, mediated by elevated expression of cytokines CXCL16 and CXCL1 present in the koPFCM, which stimulated prostate cancer cell adhesion to the bone matrix and induced proliferation at an early stage.. It is well established that stromal TGF-β signaling is important for prostate tissue development as well as prostate cancer initiation and progression (9, 26-29). TGF-β is abundant in the bone matrix, and that the release of TGF-β from the matrix is a critical component for the "vicious cycle" of osteoclastic bone metastasis (12). Inhibition of TGF-β with small-molecule inhibitors or neutralizing antibodies has previously been shown to decrease osteolytic bone lesion ...
TY - JOUR. T1 - CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma. T2 - Analysis within a group of patients, all of whom developed lung metastasis. AU - Oda, Yoshinao. AU - Yamamoto, Hidetaka. AU - Tamiya, Sadafumi. AU - Matsuda, Shuichi. AU - Tanaka, Kazuhiro. AU - Yokoyama, Ryohei. AU - Iwamoto, Yukihide. AU - Tsuneyoshi, Masazumi. PY - 2006/5/1. Y1 - 2006/5/1. N2 - The chemokine, CXCL12, and its receptor, CXCR4, have recently been shown to play an important role in metastasis of several kinds of carcinoma. It has also been demonstrated that VEGF regulates both the expression of CXCR4 and invasiveness in breast cancer cell lines. We compared the immunohistochemical expression of CXCR4 and VEGF between the primary site and a concordant pulmonary metastatic site in 30 osteosarcoma patients, all of which had undergone thoracotomy. Microvessel density (MVD) as shown by immunostaining of CD34 and proliferative activity with MIB-1 monoclonal antibody was ...
18 Apr 2017. When cancer metastases, bone unwittingly offers a friendly place for tumour cell growth--only to have its hospitality betrayed by pathologic fractures, spinal cord compression, the need for bone surgery or irradiation, and an increased risk of death.. In the largest-known study on bone metastases in thyroid cancer, researchers at the University of Michigan Comprehensive Cancer Center found that patients with follicular and medullary thyroid cancer had the highest rate of cancer-related bone lesions and fractures and an increased risk of death.. We know that metastases are bad.. But patients in our study who had bone metastases had a worse survival rate compared to patients who had metastases at other distant sites, says Megan Haymart, M.D., assistant professor of medicine at Michigan Medicine and one of the researchers on the study.. This suggests that bone metastases are a uniquely poor prognostic indicator.. However, patients with localised or regional thyroid cancer---without ...
AICAR induces mitochondrial apoptosis in human osteosarcoma cells through an AMPK-dependent pathwayAICAR induces mitochondrial apoptosis in human osteosarcoma cells through an AMPK-dependent pathway ...
Osteogenic sarcoma (also called osteosarcoma) is the most common tumor of bone. Approximately 1,000 cases of osteogenic sarcoma are seen in the United States each year. A second peak of incidence of osteosarcoma occurs in the eighth decade of life, typically associated with Paget bone disease. Osteosarcoma typically affects adolescents and generally occurs in bones around the knee joint, though any bone of the body can be affected. Treatment typically involves chemotherapy and surgery to try to achieve the best cure rate. Standard drugs include doxorubicin and cisplatin in adults and the same two drugs with high-dose methotrexate in children, adolescents, or young adults.. Recurrences typically occur in the lungs. Surgical removal of lung metastases from a primary osteosarcoma is a standard of care when there is a small number of lung nodules that can be removed safely, and can be associated with a 30-35% cure rate. Osteosarcomas occur commonly in familial syndromes associated with sarcoma, such ...
The present study demonstrates that a high level of YY1 protein expression increases the risk of metastasis (4.69-fold) and poor survival (8.35-fold) in osteosarcoma patients independently of covariates such as age, gender, histotype, and chemonecrosis. We report that the highest range of YY1 expression is a statistically significant prognostic factor setting the 5-year survival rate to 34% in patients with osteosarcoma. These results are in line with literature data and with the tumor necrosis rate which is currently the strongest clinical prognostic factor after chemotherapy [2, 23, 24].. Overall, the molecular complexity of osteosarcoma makes the known prognostic markers of limited utility [12, 25]. A multiple panel of biomarkers in addition to clinical parameters would be useful for predicting prognosis [25]. In this setting, YY1 is the first osteosarcoma marker whose overexpression has been correlated with low metastasis-free and poor overall survival in a higher frequency of cases (61% in ...
Alkaline Phosphatase, serum Bone-specific alkaline phosphatase (BAP.) When alkaline phosphatase is measured, it is actually the sum of the bone-specific and liver-specific components (isoenzymes.) BAP can indicate excess osteoblastic cell activity which may indicate bone metastases. Metra Systems, Inc., says that Bone Alkaline Phosphatase is an osteoblast membrane-bound molecule which is involved in bone formation. Levels of this enzyme are thought to be indicative of the activity of osteoblasts. Another description of AlkPhos is that it is an enzyme that is found on the surface of osteoblasts(the cells that build bone) and as such is used as a serum marker of increased osteoblast activity. Since bone is being added at prostate cancer bone metastases, an increased alkaline phosphatase can mean increased bone met formation. A recent paper by MR Smith et al in Urology discussed BAP and NTx in their role as predictors of skeletal complications in HRPC patients (MR Smith, et al, Urology 70: 315-319, ...
Primary osteogenic sarcoma of the breast is a rare clinical entity with few cases described in the literature. Unfortunately, the prognosis for these patients is poor when compared to invasive carcinomas of the breast. We report a case of a 58-year-old female who developed a primary osteogenic sarcoma of the breast five years after being treated for invasive carcinoma of the ipsilateral breast without the use of radiotherapy.
Breast cancer is the second leading cause of cancer-related death in women in the United States. During the advanced stages of disease, many breast cancer patients suffer from bone metastasis. These metastases are predominantly osteolytic and develop when tumor cells interact with bone. In vivo models that mimic the breast cancer-specific osteolytic bone microenvironment are limited. Previously, we developed a mouse model of tumor-bone interaction in which three mouse breast cancer cell lines were implanted onto the calvaria. Analysis of tumors from this model revealed that they exhibited strong bone resorption, induction of osteoclasts and intracranial penetration at the tumor bone (TB)-interface. In this study, we identified and used a TB microenvironment-specific gene expression signature from this model to extend our understanding of the metastatic bone microenvironment in human disease and to predict potential therapeutic targets. We identified a TB signature consisting of 934 genes that were
Cryoablation, a form of low-temperature thermal ablation, has a long history in the treatment of primary and metastatic neoplasms of the kidney, liver, lung, and prostate. Cryoablation is a relatively new technique in the palliative treatment of bone metastases, with the first prospective trial reported in 2006 demonstrating its safety and efficacy.. Argon gas flowing through a sealed probe creates an ice ball due to rapid expansion of the pressurized gas in the sealed probe tip, resulting in a temperature drop to -100C within seconds (Joules-Thomson effect). Helium gas is then used to attain active thawing of the ice ball. The size of the ablation depends on the diameter of the cryoprobe, the length of the uninsulated tip, and the time of freezing.. A single freeze-passive thaw-freeze cycle is performed for 10-5-10 minutes, respectively. Unlike that for RF ablation, the ablation zone in cryoablation can be monitored directly with computed tomography (CT) as a low attenuation elliptical region ...
Osteosarcoma is the most common bone tumor that occurs in dogs. Early diagnosis and intervention are key to maximizing a positive outcome.
Bone Metastases: Impact and Prevalence. Bone metastases, cancer cells that separate from tumors and migrate to bone tissue where they settle and grow, occur in more than 1.5 million people worldwide.(1) With improvements in cancer care, including earlier diagnosis and new treatment options, leading to increases in survival rates(2), the number of patients developing metastatic disease secondary to a primary cancer is increasing. Bone metastases are a significant problem for patients with certain types of advanced cancer, with incidence rates of nearly 100 percent in myeloma patients and as high as 75 percent in breast and prostate cancer patients. With bone metastases the growing cancer cells weaken and destroy the bone around the tumor. The damage the tumor has caused to the bone can result in a number of serious complications, collectively called SREs. All are serious complications for advanced cancer patients. The economic burden of U.S. patients with bone metastases is significant and is ...
Ιατρός ορθοπεδικός Αγγουλές Αντώνης . Θέματα σχετικά με οσφυαλγια ισχυαλγια αρθροσκοπηση κακωσεις-ρηξεις χιαστου και θεραπευτικες επεμβατικες προσεγγισεις.
Ιατρός ορθοπεδικός Αγγουλές Αντώνης . Θέματα σχετικά με οσφυαλγια ισχυαλγια αρθροσκοπηση κακωσεις-ρηξεις χιαστου και θεραπευτικες επεμβατικες προσεγγισεις.
Bone Pain Trial Working Party. Röntgen-Blatter; Zeitschrift fur Röntgen-Technik und medizinisch-wissenschaftliche Photographie ; 36 7: A systematic overview of radiation therapy effects in skeletal metastases. International journal of radiation oncology, biology, physics ; 55 3: Journal of the National Cancer Institute ; 97 Predictors of skeletal complications in patients with metastatic breast carcinoma. Strahlentherapie und Onkologie ; 2: International orthopaedics ; 36 6: International journal of radiation oncology, biology, physics ; 79 4: Clinical cancer research ; 12 20 Pt 2: Schober 1 for the MSDS group. Strahlentherapie und Onkologie ; 7: The stability of osseous metastases of the spine in lung cancer - a retrospective analysis of cases. Bone Pain Trial Working Party. Hämostaseologie Beste Spielothek in Villarsel finden singlebörse Fachbereich: Palliation of metastatic bone pain: Update on the systematic review of palliative radiotherapy trials Beste Spielothek in Dietring finden ...
Peter Croucher manages a highly competitive research group with an international reputation for research in bone cell biology, tumour-induced bone disease and its clinical translation. This includes research into the understanding how tumours grow in bone and cause bone disease, particularly the haematological malignancy multiple myeloma, and breast and prostate cancer bone metastasis.
Osteosarcoma (OS) is the most common primary bone tumor that affects adolescents and young adults. Disruption of microRNA (miRNA) regulation is well established in the pathophysiology of different cancers, including OS. Increased expression of miR-9 in OS positively correlates with the tumor size, clinical stage, and distant metastasis. In the present study, we used two different OS cell lines, MG-63 and Saos-2, as in vitro models. Small interfering RNA against miR-9 and miR-9 mimics were used to study the function of miR-9 in these two cell lines. We determined the effect of miR-9 inhibition on cell proliferation, cell cycle, apoptosis, and the protein expression of different genes. Our results demonstrated that miR-9 knockdown in the human OS cell lines inhibits their metastatic potential, as determined by decreased cell proliferation and cell cycle arrest, decreased invasion, and increased apoptosis. The western blot analysis showed that cadherin-1 (CDH1), matrix metalloproteinase 13 ...
Sm153-EDTMP IV is equivalent to opioid treatment against cancer pain for patients with multiple bone metastasis, and is cost-effective. (J BUON. 2014 Oct-Dec;19(4):1083-91.) ...
Men with prostate cancer and bone metastases that have experienced at least one skeletal-related event (SRE) show worse survival, according to a recent study.
THOUSAND OAKS, Calif., Feb. 24, 2011 /PRNewswire via COMTEX/ --. Amgen (Nasdaq: AMGN) today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA(TM) (denosumab) to Zometa(R) (zoledronic acid) in preventing bone complications called skeletal-related events (SREs) in 1,901 men with prostate cancer and bone metastases. The study, published in The Lancet, met its primary and secondary endpoints and demonstrated XGEVAs superiority compared to Zometa in preventing SREs. XGEVA was approved by the U.S. Food and Drug Administration (FDA) on Nov. 18, 2010 for the prevention of SREs in patients with bone metastases from solid tumors, including prostate cancer. XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma. XGEVA, the first and only FDA-approved RANK Ligand inhibitor, is the first new treatment for advanced cancer patients with bone metastases in nearly a decade. "Bone metastases represent a significant risk for advanced prostate ...
Background: 15,16-dihydrotanshinone I (DHTI), a lipophilic tanshinone extracted from Danshen root (Salvia miltiorrhiza Bunge), has been reported to function as an antitumor agent. However, its activity on osteosarcoma (OS), the most common primary malignant bone tumor, is unclear.. Objective: This study aimed to determine the effects of DHTI treatment on proliferation, apoptosis and migration of human OS cell line 143B and investigate the possible underlying molecular mechanisms.. Method: Human cell line 143B was used as a model for investigation of the inhibitory effects of DHTI on osteosarcoma. Cell proliferation was evaluated by MTT assays, while cell cycle progression, apoptosis and cell migration were analyzed by flow cytometer, caspase activity assays and scratch migration assays. qRT-PCR and western blot were carried out to detect the expression levels of representative genes and proteins during physiological processes examined above.. Results: DHTI treatment inhibited the proliferation ...
Trisacryl gelatin microspheres versus polyvinyl alcohol particles in the preoperative embolization of bone neoplasms. - Antonio Basile, Thomas Rand, Fritz Lomoschitz, Cyril Toma, Tommaso Lupattelli, Joachim Kettenbach, Johannes Lammer
The goals of this study were to 1) demonstrate that the MTA rat mammary adenocarcinoma cell line is nonresponsive to treatment with the bisphosphonate risedronate and 2) compare the in vitro cellular responses of the MTA (nonresponder) and a related rat mammary adenocarcinoma cell line, MTB-01 (responder) to risedronate in order to identify factors responsible for the MTA cell lines response to bisphosphonate treatment.,To establish the MTA cell line as nonresponsive to risedronate treatment, Berlin- Druckery rats received an intracardiac injection of 105 MTA cells. Risedronate was administered daily to test animals beginning on the day of tumor cell inoculation. Control animals received MTA cells and daily saline injections. Animals were euthanized on day 14 and metastatic bone lesions were enumerated and area measurements were taken microscopically from femurs and vertebrae. There was no statistically significant difference in the size or number of metastatic foci in treated verses untreated ...
Desmoplastic fibroma (DF) is a rare, benign but locally aggressive, intraosseous lesion with a high tendency of local recurrence. In this report the actual literature is reviewed regarding epidemiological data, pathology, clinical diagnostic criterias, therapy and prognosis. Moreover, a report of an interesting case is included localized in the mandibular corpus.
August 10, 2009 - Limb-sparing surgery, which has been taking the place of amputation for bone and soft tissue sarcomas of the lower limb in recent years, may not provide much or even any additional benefit to patients according to a new review. The analysis, published in the September 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, indicates that patients and physicians should rethink the pros and cons of limb-sparing surgery and amputation.. Patients with tumors of the bone or soft tissue in their arms and legs require surgery to remove their cancer. To compare the costs and benefits of amputation compared with limb-sparing surgery in these patients, Canadian researchers Ronald Barr, M.D., M.B., Ch.B., of McMaster University and Jay Wunder, M.D., M.Sc., of the Mount Sinai Hospital and the University of Toronto reviewed all published papers on limb-sparing surgery that also measured patients functional health and quality of life.. The review found that while ...
TY - JOUR. T1 - Flavonoids purified from Rhus verniciflua Stokes actively inhibit cell growth and induce apoptosis in human osteosarcoma cells. AU - Jang, Hyon Seok. AU - Kook, Sung Ho. AU - Son, Young Ok. AU - Kim, Jong Ghee. AU - Jeon, Young Mi. AU - Jang, Yong Suk. AU - Choi, Ki Choon. AU - Kim, Ju. AU - Han, Seong Kyu. AU - Lee, Kyung Yeol. AU - Park, Byung Keon. AU - Cho, Nam Pyo. AU - Lee, Jeong Chae. PY - 2005/11/30. Y1 - 2005/11/30. N2 - Many studies have suggested that dietary flavonoids are anticancer agents that induce the apoptosis of cancer cells. However, the effects of flavonoids on the induction of apoptosis in osteosarcoma cells are unclear. Previously, a flavonoid fraction, consisting mainly of protocatechuic acid, fustin, fisetin, sulfuretin, and butein, herein named RCMF (the RVS chloroform-methanol fraction), was prepared from a crude acetone extract of Rhus verniciflua Stokes (RVS). This study evaluated the effects of RCMF on the proliferation and apoptosis using human ...
for treating castration resistant prostate cancer and symptomatic bone metastases. From the website below: "The active moiety of Xofigo is the alpha particle-emitting isotope radium 223 (as radium 223 dichloride), which mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases. The high linear energy transfer of alpha emitters (80 keV/micrometer) leads to a high frequency of double-strand DNA breaks in adjacent cells, resulting in an anti-tumor effect on bone metastases. The alpha particle range from radium 223 dichloride is less than 100 micrometers (less than 10 cell diameters) which limits damage to the surrounding normal tissue. After intravenous injection, radium 223 is rapidly cleared from the blood and is distributed primarily into bone or is excreted into intestine. Fifteen minutes post-injection, about 20% of the injected radioactivity remained in blood. At 4 hours, about 4% of the injected radioactivity remained ...
Osteochondroma may develop as a solitary or multiple lesions which are known as hereditary multiple exostoses (HME). The incidence rate of HME is about 12 % of all osteochondromas (Gille et al. 2005). Particularly, the incidence of osteochondroma in the spine is reported to be very rare in the literature (Khosla et al. 1999). The spinal involvement of HME is about 7-9 % (Giudicissi-Filho et al. 2006), whereas that of solitary osteochondroma is about 1-4 % (Chooi et al. 2005). This tumor can occur in any vertebrae of the spine, but the cervical spine is commonly involved in about 50 % (Murphey et al. 2000). The most frequent site is the C2 vertebral bone, followed by C3 and C6 (Chatzidakis et al. 2007; Maheshwari et al. 2006; Schomacher et al. 2009). Osteochondroma typically occurs in young patients, but those of the spine usually occur during the second to third decades of life (Bess et al. 2005; Sakai et al. 2002). Sakai et al. suggested that degenerative changes of the vertebrae might ...

Trisacryl gelatin microspheres versus polyvinyl alcohol particles in the preoperative embolization of bone neoplasms. |...Trisacryl gelatin microspheres versus polyvinyl alcohol particles in the preoperative embolization of bone neoplasms. |...

Trisacryl gelatin microspheres versus polyvinyl alcohol particles in the preoperative embolization of bone neoplasms. - Antonio ... Trisacryl gelatin microspheres versus polyvinyl alcohol particles in the preoperative embolization of bone neoplasms.. Abstract ... in the preoperative embolization of bone neoplasms, on the basis of intraoperative blood loss quantified by the differences in ... From January 1997 to December 2002, preoperative embolization of bone tumors (either primary or secondary) was carried out in ...
more infohttp://www.curehunter.com/public/pubmed15383854.do

Benign periarticular, bone and joint lipomatous lesions | SMJBenign periarticular, bone and joint lipomatous lesions | SMJ

Keywords: benign neoplasms, bone neoplasms, lipoma, soft tissue neoplasms INTRODUCTION. Benign periarticular, bone and joint ... Intraosseous lipoma is a rare, benign bone lesion with a cited prevalence of less than 0.1% of bone tumours reported.(1,6) The ... Intraosseous lipoma in the femoral shaft mimicking a bone metastasis on bone scintigraphy.. Clin Nucl Med. 2009. ;. 34. :. 693 ... Intraosseous lipoma in the femoral shaft mimicking a bone metastasis on bone scintigraphy. Clin Nucl Med 2009; 34:693-5.. https ...
more infohttp://www.smj.org.sg/article/benign-periarticular-bone-and-joint-lipomatous-lesions

Oral lipoma: Many features of a rare oral benign neoplasm | IRInSubriaOral lipoma: Many features of a rare oral benign neoplasm | IRInSubria

Infrequent locations of orofacial lipomas include the maxillary bones, especially the mandible. Among lipomas, different ... The unusual characteristics of this case report were the large-sized dimensions of the neoplasm, which were 3 cm along the main ... Introduction Lipomas are common benign soft tissue neoplasms composed of mature white adipocytes. They are the most common soft ... tissue mesenchymal neoplasms. However, they are relatively uncommon in the oral and maxillofacial regions. Their overall ...
more infohttps://irinsubria.uninsubria.it/handle/11383/2023163

Management of giant intermuscular lipoma of hips: A case report and review of literatureManagement of giant intermuscular lipoma of hips: A case report and review of literature

Generally, intermuscular lipomas have a well-defined pseudo-capsule (3,12,21), thus, dissection around these benign neoplasms ... on the post-lateral side of the greater trochanter of the femur bone. The lump was smooth-surfaced, immobile, had increased ...
more infohttps://spandidos-publications.com/mco/1/2/369

US-guided biopsy performs well for evaluating bone neoplasmsUS-guided biopsy performs well for evaluating bone neoplasms

... By Erik L. Ridley, AuntMinnie staff writer. January 21, 2015 -- ... biopsy of bone neoplasms yields similar accuracy to CT-guided biopsy for evaluating primary and metastatic bone lesions, while ... set out to compare the diagnostic accuracy of ultrasound-guided biopsy with CT-guided biopsy for primary and metastatic bone ...
more infohttps://www.auntminnie.com/index.aspx?sec=log&URL=https:%2F%2Fwww.auntminnie.com%2Findex.aspx%3Fsec%3Dlog%E2%8A%82%3Dpas%E2%88%A8iginalURL%3Dhttps:%252F%252Fwww.auntminnie.com%252Findex.aspx%253Fsec%253Dnws%2526sub%253Drad%2526pag%253Ddis%2526itemId%253D109836

NCT00381095 | Bone Neoplasms, Intractable Pain, Cancer Clinical Trial | PfizerNCT00381095 | Bone Neoplasms, Intractable Pain, Cancer Clinical Trial | Pfizer

Pfizer is currently recruiting for the NCT00381095 Bone Neoplasms, Intractable Pain, Cancer Cancer trial. Review trial ...
more infohttps://www.pfizer.com/science/find-a-trial/nct00381095

US-guided biopsy performs well for evaluating bone neoplasmsUS-guided biopsy performs well for evaluating bone neoplasms

... By Erik L. Ridley, AuntMinnie staff writer. January 21, 2015 -- ... biopsy of bone neoplasms yields similar accuracy to CT-guided biopsy for evaluating primary and metastatic bone lesions, while ... set out to compare the diagnostic accuracy of ultrasound-guided biopsy with CT-guided biopsy for primary and metastatic bone ...
more infohttps://www.auntminnie.com/index.aspx?sec=log&URL=https%3A%2F%2Fwww.auntminnie.com%2Findex.aspx%3Fsec%3Dlog%E2%8A%82%3Dexa%26provider%3Dlinkedin%E2%88%A8iginalURL%3Dhttps%3A%252F%252Fwww.auntminnie.com%252Findex.aspx%253Fsec%253Dlog%E2%8A%82%253Dpas%E2%88%A8iginalURL%253Dhttps%3A%25252F%25252Fwww.auntminnie.com%25252Findex.aspx%25253Fsec%25253Dnws%252526sub%25253Drad%252526pag%25253Ddis%252526itemId%25253D109836

Primary bone neoplasms in dogs: 90 casesPrimary bone neoplasms in dogs: 90 cases

... malignant bone neoplasms in dogs were much more prevalent than the benign ones, (2); OS were the most prevalent bone neoplasms ... of all malignant bone neoplasms observed in this study. Other malignant bone neoplasms diagnosed, in descending order of ... Clinical signs associated with primary bone neoplasms depend much more on the location than on the type of the neoplasm itself ... Osteosarcoma was the most prevalent bone tumor, accounting for 86.7% of all malignant primary bone neoplasms diagnosed. Most ...
more infohttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-736X2012001200018&lng=en&tlng=en

Bone Tissue Neoplasms
      - Tissue Neoplasms, Bone
     Summary Report | CureHunterBone Tissue Neoplasms - Tissue Neoplasms, Bone Summary Report | CureHunter

The concept does not refer to neoplasms located in bones. ... Neoplasms composed of bony tissue, whether normal or of a soft ... Tissue Neoplasms, Bone; Neoplasms, Bone Tissue; Bony Tissue Neoplasms; Neoplasms, Bony Tissue; Bone Tissue Neoplasm; Bony ... Tissue Neoplasm; Neoplasm, Bone Tissue; Neoplasm, Bony Tissue; Tissue Neoplasm, Bone; Tissue Neoplasm, Bony; Tissue Neoplasms, ... Bone Tissue Neoplasms (Tissue Neoplasms, Bone). Subscribe to New Research on Bone Tissue Neoplasms ...
more infohttp://www.curehunter.com/public/keywordSummaryD018213-Bone-Tissue-Neoplasms-Tissue-Neoplasms--Bone.do

A hostel for the hostile: the bone marrow niche in hematologic neoplasms | HaematologicaA hostel for the hostile: the bone marrow niche in hematologic neoplasms | Haematologica

Mineralized bone was also lost. The cytokine CCL3, known to be involved in bone loss, was increased in AML cells in mice and ... The normal bone marrow anatomy (here using the example of the femur) is composed of different types of bone, blood vessels and ... It was shown that PTHinduced bone remodeling led to a release of su-praphysiological levels of TGFβ1 from the bone matrix ... A hostel for the hostile: the bone marrow niche in hematologic neoplasms ...
more infohttp://www.haematologica.org/content/100/11/1376

Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. | JEMExclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. | JEM

Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles.. W S Pear, ... Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. ... Using a bone marrow reconstitution assay with cells containing retrovirally transduced TAN1 alleles, we analyzed the oncogenic ... Moreover, the murine tumors caused by TAN1 in the bone marrow transplant model are very similar to the TAN1-associated human ...
more infohttp://jem.rupress.org/content/183/5/2283?ijkey=a06392ead9eef6ba7b1ccf9bbcbda4dec7b4c308&keytype2=tf_ipsecsha

ICD-9-CM Diagnosis Code 213.1 : Benign neoplasm of lower jaw boneICD-9-CM Diagnosis Code 213.1 : Benign neoplasm of lower jaw bone

long bones (M9261/3) - see Neoplasm, bone, malignant. *. malignant (M9310/3) 170.1. *. jaw (bone) (lower) 170.1. *. upper 170.0 ... Home > 2015 ICD-9-CM Diagnosis Codes > Neoplasms 140-239 > Benign Neoplasms 210-229 > Benign neoplasm of bone and articular ... adenomatoid (M9054/0) - see also Neoplasm, by site, benign*. odontogenic (M9300/0) 213.1*. upper jaw (bone) 213.0. ... Fibroma (M8810/0) - see also Neoplasm, connective tissue, benign*. ameloblastic (M9330/0) 213.1*. upper jaw (bone) 213.0. ...
more infohttp://www.icd9data.com/2015/Volume1/140-239/210-229/213/213.1.htm

Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles  -...Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles -...

Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles ... Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. Journal of ... Using a bone marrow reconstitution assay with cells containing retrovirally transduced TAN1 alleles, we analyzed the oncogenic ... Moreover, the murine tumors caused by TAN1 in the bone marrow transplant model are very similar to the TAN1-associated human ...
more infohttps://authors.library.caltech.edu/12364/

ICD-9-CM Diagnosis Code 213.0 : Benign neoplasm of bones of skull and faceICD-9-CM Diagnosis Code 213.0 : Benign neoplasm of bones of skull and face

Home > 2015 ICD-9-CM Diagnosis Codes > Neoplasms 140-239 > Benign Neoplasms 210-229 > Benign neoplasm of bone and articular ... adenomatoid (M9054/0) - see also Neoplasm, by site, benign*. odontogenic (M9300/0) 213.1. *. upper jaw (bone) 213.0 ... Fibroma (M8810/0) - see also Neoplasm, connective tissue, benign*. ameloblastic (M9330/0) 213.1. *. upper jaw (bone) 213.0 ... Myxofibroma (M8811/0) - see also Neoplasm, connective tissue, benign*. odontogenic (M9320/0) 213.1. *. upper jaw (bone) 213.0 ...
more infohttp://www.icd9data.com/2015/Volume1/140-239/210-229/213/213.0.htm

Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic AcidBone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid

... ... in patients with bone metastases (BM). In neuroendocrine neoplasms (NEN), BM are a negative prognostic factor, however tend to ... in Patients with Bone Metastases of Neuroendocrine Neoplasms. Introduction: Antiresorptive therapy (ART) with bisphosphonates ... Keywords: bone metastases, skeletal related event, survival, bisphosphonates, 68Ga-PET, 18FDG-PET, CT scan ...
more infohttps://www.enets.org/bone-metastases-and-skeletal-related-events-in-patients-with-neuroendocrine-neoplasms-nen-the-role-of-zoledronic-acid.html

How Often Should MPN Patients Have a Bone Marrow Biopsy?  | Myeloproliferative Neoplasms | Patient PowerHow Often Should MPN Patients Have a Bone Marrow Biopsy? | Myeloproliferative Neoplasms | Patient Power

Stephen Oh discuss their views on when and why patients should have a bone marrow biopsy. ... How often should MPN patients have a bone marrow biopsy? Dr. Brady Stein and Dr. ... How often should MPN patients have a bone marrow biopsy? Dr. Brady Stein and Dr. Stephen Oh discuss their views on bone marrow ... Also, we look to see how actionable a bone marrow might be. Am I going to respond to it? Am I going to change your therapy? Am ...
more infohttps://www.patientpower.info/video/how-often-should-mpn-patients-have-a-bone-marrow-biopsy

2020 ICD-10-CM Diagnosis Code D16.4: Benign neoplasm of bones of skull and face2020 ICD-10-CM Diagnosis Code D16.4: Benign neoplasm of bones of skull and face

Benign neoplasm of bones of skull and face. 2016 2017 2018 2019 2020 Billable/Specific Code *D16.4 is a billable/specific ICD- ... Benign neoplasm of bone and articular cartilage. 2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code Type 1 Excludes*benign ... Benign neoplasm of lower jaw bone. 2016 2017 2018 2019 2020 Billable/Specific Code Applicable To*Keratocyst of mandible ... Benign neoplasm of lower jaw bone. 2016 2017 2018 2019 2020 Billable/Specific Code Applicable To*Keratocyst of mandible ...
more infohttps://www.icd10data.com/ICD10CM/Codes/C00-D49/D10-D36/D16-/D16.4

2020 ICD-10-CM Diagnosis Code D16.12: Benign neoplasm of short bones of left upper limb2020 ICD-10-CM Diagnosis Code D16.12: Benign neoplasm of short bones of left upper limb

D16.0 Benign neoplasm of scapula and long bones of upper limb D16.00 Benign neoplasm of scapula and long bones of unspecified ... Benign neoplasm of short bones of left upper limb. 2016 2017 2018 2019 2020 Billable/Specific Code *D16.12 is a billable/ ... Benign neoplasm, short bone of left arm. ICD-10-CM D16.12 is grouped within Diagnostic Related Group(s) (MS-DRG v37.0): *564 ... Benign neoplasm of bone and articular cartilage. 2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code Type 1 Excludes*benign ...
more infohttps://www.icd10data.com/ICD10CM/Codes/C00-D49/D10-D36/D16-/D16.12

JCDR -
        Bone Repair, Gene transfer techniques, Growth factor, NeoplasmsJCDR - Bone Repair, Gene transfer techniques, Growth factor, Neoplasms

Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.
more infohttp://www.jcdr.net/article_fulltext.asp?issn=0973-709x&year=2017&month=October&volume=11&issue=10&page=ZE01-ZE05&id=10703

Secondary malignant neoplasm of bone and bone marrow - RightDiagnosis.comSecondary malignant neoplasm of bone and bone marrow - RightDiagnosis.com

Secondary malignant neoplasm of bone and bone marrow information including symptoms, causes, diseases, symptoms, treatments, ... Bone and bone *Malignant neoplasm *Bone marrow *Bone marrow symptoms *Bone marrow disease *Bone marrow disorder *Malignant * ... Neoplasm (16 causes) *Neoplasm pain *Bone Hierarchical classifications of Secondary malignant neoplasm of bone and bone marrow ... Secondary malignant neoplasm of bone and bone marrow: Related Topics. These medical condition or symptom topics may be relevant ...
more infohttps://www.rightdiagnosis.com/medical/secondary_malignant_neoplasm_of_bone_and_bone_marrow.htm

Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. | Journal...Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. | Journal...

Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. W S Pear, W ... Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles.. J Exp Med ... Using a bone marrow reconstitution assay with cells containing retrovirally transduced TAN1 alleles, we analyzed the oncogenic ... Moreover, the murine tumors caused by TAN1 in the bone marrow transplant model are very similar to the TAN1-associated human ...
more infohttps://rupress.org/jem/article/183/5/2283/57688/Exclusive-development-of-T-cell-neoplasms-in-mice

MedPix Topic - primary bone neoplasm, chondro-osseous variantsMedPix Topic - primary bone neoplasm, chondro-osseous variants

24 yo man with right-sided lower posterior chest/rib pain for 4-6 months, increases with deep inspiration. He denies history of trauma.
more infohttps://medpix.nlm.nih.gov/topic?id=f7349f9d-b047-4750-80db-c698e97f9d9f&quiz=t

Neoplasms, Bone TissueNeoplasms, Bone Tissue

Build: Wed Jun 21 18:33:50 EDT 2017 (commit: 4a3b2dc). National Center for Advancing Translational Sciences (NCATS), 6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-435-0888. ...
more infohttps://pharos.nih.gov/idg/diseases/umls:C0206639

primary bone neoplasmsprimary bone neoplasms

... metabolic bone disease, metastatic neoplasms, mri, osteoporosis, pain, physical therapy, primary bone neoplasms, radiography, ...
more infohttps://www.orthopaedicclinic.com.sg/tag/primary-bone-neoplasms/
  • Given that leukemia does not propagate just anywhere in the body and is difficult to grow ex vivo , it was thought that leukemia cells depend on the bone marrow microenvironment (BMM). (haematologica.org)
  • So I think if there's something different about you, your blood or your bone marrow, that becomes an indication. (patientpower.info)
  • The Pathology and Laboratory Quality Center (the Center) of the College of American Pathologists (CAP) has advanced blood cancer diagnostics by developing recommendations to standardize the basic components of a synoptic report template for bone marrow samples. (cap.org)
  • Thus, although all blood cells, even lymphocytes, are normally born in the bone marrow in adults, myeloid cells in the narrowest sense of the term can be distinguished from lymphoid cells, that is, lymphocytes, which come from common lymphoid progenitor cells that give rise to B cells and T cells. (wikipedia.org)
  • Transcatheter-Arterial embolization (TAE) is an established regional, palliative treatment option for liver metastases in patients (pts) with neuroendocrine neoplasms (NENs). (enets.org)
  • Antiresorptive therapy (ART) with bisphosphonates or denosumab is effective in preventing skeletal-related events (SREs) in patients with bone metastases (BM). (enets.org)